



Mechanisms of extramedullary relapse in acute lymphoblastic leukemia Reconciling biological concepts and clinical issues

J. Gaudichon, H. Jakobczyk, L. Debaize, E. Cousin, M.-D. Galibert, M.-B. Troadec, V. Gandemer

► To cite this version:

J. Gaudichon, H. Jakobczyk, L. Debaize, E. Cousin, M.-D. Galibert, et al.. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia Reconciling biological concepts and clinical issues. *Blood Reviews*, 2019, 36, pp.40-56. 10.1016/j.blre.2019.04.003 . hal-02132591

HAL Id: hal-02132591

<https://univ-rennes.hal.science/hal-02132591>

Submitted on 16 Jul 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Title: Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: reconciling biological concepts and clinical issues

Short Title: Acute Leukemia Extramedullary Relapses

Authors: Jérémie Gaudichon^{1,3}, Hélène Jakobczyk¹, Lydie Debaize¹, Elie Cousin^{1,2}, Marie-Dominique Galibert¹, Marie-Bérengère Troadec¹, and Virginie Gandemer^{1,2}.

Affiliations: ¹Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes) - UMR 6290, F- 35000 Rennes, France

²Pediatric Hematology Department, University Hospital, Rennes, France

³Pediatric Hematology and Oncology Department, University Hospital, Caen, France

Corresponding author:

Prof. Virginie Gandemer,

Pôle Femme-Enfant

Service d'hémo-oncologie pédiatrique

CHU Hôpital Sud- 16 Bd de Bulgarie - 35203 Rennes Cedex 2

Email: virginie.gandemer@chu-rennes.fr

Telephone: (+ 33)2 23 23 70 24; Fax: (+33) 2 99 26 71 95

or

Dr Jérémie Gaudichon

Onco-hématologie pédiatrique

CHU de Caen

22 Avenue de la côte de nacre
23 14033 CAEN Cedex 9
24 Telephone: (+33) 2 31 06 26 81
25 Email: gaudichon-j@chu-caen.fr
26 **Email of the other authors:**
27 lydie.debaize@gmail.com
28 helenejakobczyk@gmail.com
29 mgaliber@univ-rennes1.fr
30 berengere.troadec@gmail.com

31 **Table of contents**

Abstract	4
I.Introduction	5
II.Cellular origin of relapse	6
III.Sites of relapse	8
1.Different microenvironments	9
a)Bone marrow (Figure 2a)	9
b)Gonads (Figure 2b)	9
c)Central nervous system (Figure 2c)	11
d)Others	12
2.Similarities between sanctuary sites.....	13
a)The concept of “niche”	13
b)CXCL12/CXCR4	14
c)Oxygen content.....	17
Stem cell factor.....	19
d)Other shared factors	21
IV.The interplay between leukemic cells and the microenvironment	23
1.Leukemic and cancer cells model their niche	23
2.Means of communication between ALL cells and supportive cells	25
3.The chicken or the egg causality dilemma in ALL relapses.....	29
V.From bench to bedside	31
VI.Therapeutic challenges.....	34
VII.Conclusion and future directions	35
VIII.Practice points	36
IX.Research agenda.....	37
REFERENCES	37

32

Abstract

Long-term survival rates in childhood acute lymphoblastic leukemia (ALL) are currently above 85% due to huge improvements in treatment. However, 15-20% of children still experience relapses. Relapses can either occur in the bone marrow or at extramedullary sites, such as gonads or the central nervous system (CNS), formerly referred to as ALL-blast sanctuaries. The reason why ALL cells migrate to and stay in these sites is still unclear. In this review, we have attempted to assemble the evidence concerning the microenvironmental factors that could explain why ALL cells reside in such sites. We present criteria that make extramedullary leukemia niches and solid tumor metastatic niches comparable. Indeed, considering extramedullary leukemias as metastases could be a useful approach for proposing more effective treatments. In this context, we conclude with several examples of potential niche-based therapies which could be successfully added to current treatments of ALL.

Keywords: acute lymphoblastic leukemia; niche; cellular microenvironment; children; relapse; extramedullary; sanctuary; bone marrow; central nervous system; testis

47 I. Introduction

48 Acute lymphoblastic leukemia (ALL) is a hematological malignancy defined by the
49 clonal expansion and accumulation of abnormal immature lymphoid precursor cells in the
50 bone-marrow (BM) compartment. This abnormal cell population replaces normal
51 hematopoietic cells and can spread from the BM to the entire body through systemic
52 circulation. Relatively rare relative to other hematological malignancies in adults, ALL is the
53 most frequent malignancy found in children and accounts for approximately 80% of
54 childhood leukemia, with a maximal incidence rate between one and six years [1]. Over the
55 last decades, the use of multi-agent chemotherapy protocols, better patient stratification into
56 risk-adapted groups for treatment, and improved treatments have drastically reduced the
57 mortality of this young population. Indeed, survival rates have risen from approximately 10%
58 in the 1960s to above 90% for children in high-income countries in the 2000s.

59 However, approximately 15 to 20% of children and approximately 50% of adult patients
60 still relapse [2–6]. This situation is defined as the resurgence of blast cells after the
61 achievement of complete remission. Relapses are generally classified and stratified according
62 to three prognostic factors: time of relapse, site of relapse, and immunophenotype B or T
63 [7]. The time of relapse, relative to the beginning and end of treatment, is the most important
64 prognostic factor: the earlier the relapse occurs, the worse the prognosis. The definition of
65 relapse is slightly different depending on the classification used (Berlin-Frankfurt-Münster
66 [BFM] or Children Oncology Group [COG]) [3,7]. The most important factor after timing is
67 probably the anatomical sites of relapse, which are commonly divided into bone marrow
68 (BM) alone (worst prognosis), extramedullary alone (best prognosis), and combined relapses
69 (intermediate prognosis). Although immunophenotype T was initially associated with poor
70 survival and is still used in tumor classification, its prognostic value appears to be less
71 important due to better stratification [8]. Furthermore, the assessment of early minimal

residual disease (MRD) is also used to predict the prognosis of patients presenting a relapse, as it is for newly-diagnosed ALL [9–12]

Given the considerable therapeutic progress that has been made, one of the main goals is to attenuate treatment-related sequelae by reducing their toxicity, while continuing to improve current survival rates. Decreasing the incidence of relapse and identifying optimal treatments and therapeutic strategies when relapse occurs, are critical goals as well. Indeed, deciphering the underlying mechanisms that lead to relapse and understanding how and why relapses occur is a prerequisite to defining new treatment approaches.

In this review, we will begin with a brief overview of the principal mechanisms involved in ALL relapses. Second, we will describe where ALL cells reside within some sites of relapse and compare medullary, extramedullary, and metastatic niches, using a few examples. We will show how their microenvironments can be considered to be quite similar. Third, we will discuss the interplay between ALL cells and the microenvironments they colonize. Fourth, we will discuss the potential predisposition of some ALL cells to reside in specific niches. Finally, we will conclude with therapeutic perspectives related to microenvironment targeting.

II. Cellular origin of relapse

Multiple biological factors may contribute to the emergence of ALL relapses [13]. Cumulative evidence suggests a clonal origin of ALL [14]. It has previously been shown that clonal evolution is involved in relapse, with the possible emergence of subclones derived either from the major clone found at initial diagnosis, minor subclones, or a common ancestral pre-leukemic clone (Figure 1) [15–20]. Several studies have described chemoresistance-related mutations in the BM samples of relapsed patients, such as those that affect the glucocorticoid response pathway (mutations of the glucocorticoid receptor gene *NR3C1* or

96 other genes, interfering with its function, such as *BTG1*) or nucleotide metabolism (for
97 example, *NT5C2* or *PRSP1* genes [13,21–25]. Clonal heterogeneity is a common feature in
98 ALL. Clonal evolution is likely to be a dynamic process in which selection plays a central
99 role, as in the Darwinian model [14,26]. Both intrinsic and extrinsic factors, such as
100 microenvironmental conditions or chemotherapeutic pressure, may favor a clone from which
101 the relapse can develop.

102 Relapses may originate from a chemoresistant clone, either already present as a minor
103 clone at diagnosis or resulting from the acquisition of secondary mutations during treatment.
104 Aside from chemoresistance mechanisms, relapse can also be explained by the presence of
105 dormant cells within the bulk population. These rare, non-dividing, quiescent cells are less
106 sensitive to cytotoxic agents. They can therefore resist treatment and give rise to a new
107 population after reentering the cell cycle, leading to relapse. Aside from the quiescent state
108 itself, cells may also exert their resistance by residing in niches where the microenvironment
109 confers protection from chemotherapy. Indeed, drug concentrations may be lower in niches, as
110 suggested for brain and testicular tissues [27,28]. Local conditions, the cell matrix, cell-cell
111 interactions, and soluble factors may also maintain quiescence. The origin of such dormant
112 cells is still an open question, but recent studies have provided some clues to their existence at
113 diagnosis [29,30]. Why and how they reenter the cell cycle and proliferate to induce relapse
114 still needs to be addressed for understanding the evolution of these dormant cells. How such
115 cells reach and invade distant favorable microenvironments from their native marrow niche is
116 also yet to be elucidated.

117 Metastasis is the spread of cancer cells from the tissue where they first originate to
118 another distant one. ALL relapses occur most often in the BM, whereas extramedullary
119 relapses are less commonly reported. Nevertheless, the occurrence of relapse is generally
120 thought to be a leukemic event, depending mainly on internal properties of the blast,

regardless of the type of relapse. However, the occurrence of relapse may not depend only on leukemic cell features, but also on the microenvironment. In the next section, we will describe the most frequently-reported sites of relapse and the concept of niches, proposing that extramedullary leukemia relapse is similar to that of solid tumor metastasis, anticipating a major role of the microenvironment of extramedullary sites.

III. Sites of relapse

Relapse can occur in the BM, the native niche from where the disease spreads at the onset. It can also emerge from extramedullary sites, such as the central nervous system (CNS) or gonads. Both used to be called “sanctuary sites”, because of the relative protection these sites appear to offer to blast cells from systemic chemotherapy. At these sites, the tissue-blood barrier is an obstacle to drug delivery [27,31,32]. Although CNS and testicular relapses may be more common in children, they also concern adults. These sites may represent the first extramedullary sites colonized by leukemic cells but can also be colonized secondary to other extramedullary sites that may have evaded clinical detection. Prophylactic cranial irradiation was added to systemic chemotherapy treatment in the 1970s to attempt to prevent CNS relapses [33]. Intrathecal chemotherapy and the use of high-dose methotrexate for neuro-meningeal prophylaxis have progressively replaced irradiation, with good results for diminishing neurological sequelae, showing that the blood-tissue barrier problem can be bypassed [34]. Similarly, treatment intensification, with the introduction of intermediate and high-dose methotrexate, has significantly decreased the incidence of testicular relapses, thus considerably improving the historically worse prognosis for boys [35,36]. However, extramedullary relapses are still a problem and have been reported in many other organs. Several studies have reported that extramedullary relapses occur in approximately 40% of cases (approximately 20% combined and 20% presumably isolated) [3,8,37]. Here, we summarize the evidence that shows the role of the microenvironment in extramedullary relapses.

1. Different microenvironments

a) Bone marrow (Figure 2a)

BM is the most frequent site of ALL relapse and is involved as an isolated or combined site of relapse in 75-90% of cases [3,8,38–41]. BM relapses are most often the unique site involved (approximately 65% of cases) [3,8,34–37]. There is no clear evidence for a privileged BM site in which lymphoblasts primarily reside. Indeed, contrary to BM aspirates, BM biopsy results are generally not given in published studies, and almost all studies presenting BM biopsy data concern patients with advanced disease. In contrast, the engraftment of leukemic cells in BM has been well-studied in murine models [42–45]. In these models, leukemic cells engraft and proliferate in specific and restricted perivascular regions, in which C-X-C motif chemokine ligand 12 (CXCL12) and E-selectin are expressed, and which overlap with perivascular niches of hematopoietic progenitors. CXCL12 appears to be required for the diapedesis of leukemic cells [42]. Leukemic cells migrate and arrest in vessels close to endosteum, where they settle. From these perivascular endosteal niches, they may proliferate and spread to the BM and beyond [44].

b) Gonads (Figure 2b)

Large group studies have reported that isolated testicular relapses could account for 3.5-8% of ALL relapses in children (including boys and girls) followed for up to 20 years [3,8,38–41,46]. Most studies mentioning testicular biopsies in the context of ALL did not indicate the precise location of blasts [47–49]. Such information can be retrieved from rare and old clinical studies and animal models [50–56]. Animal models indicate that leukemic cells infiltrate the interstitial testicular tissue mainly at the perivascular and peritubular regions, forming small foci, notably in subcapsular areas. Despite perivascular interstitial invasion, extensive infiltration of the interstitium is rare. On the other hand, the epididymis is

more often massively invaded by blast cells [54,55]. Leukemic invasion seems to occur through the hematogenous route, with possible extension to the epididymis *via* the lymphatic route [55]. In these models, although seminiferous tubules were degenerated or destroyed near leukemic infiltrations, leukemic cells were never found in the tubules nor the gonadal duct [54–56]. Unlike these *in vivo* studies, testicular leukemic infiltration was mostly found to be diffuse in a postmortem series of children who died of very advanced leukemia. Leukemic cells were found in the tubules in half the patients with heavily infiltrated testes [57]. This relatively old study included children with uncontrolled leukemia at a time when outcomes were poor and probably does not reflect the route of initial invasion. Thus, it seems that leukemic cells invade the testis by the hematogenous route and first infiltrate the perivascular and peritubular spaces, where they can spread to the epididymis through the local lymphatic system. Without effective treatment, seminiferous tubules may be destroyed and invaded as well. This is concordant with the perivascular and peritubular interstitial infiltration observed in patients with testicular relapse leukemia [50–52].

Although less commonly involved than the testis, ovaries may also be involved in ALL [58]. Ovarian relapses are scarcely reported in clinical trials [40,59], but autopsies have provided evidence of ovarian disease in end-stage leukemia [57,60,61]. More recently, ovarian involvement was found in approximately 8% of leukemia cases in an autopsy series, regardless of age. However, the authors did not indicate whether the patients had been treated or not, nor the treatment performed [62]. The effects of chemotherapy could explain the differences observed between and within the reports mentioned above, in which ovarian involvement was found in 3% to up to 50% of cases [57,60,61]. Indeed, Pais *et al.* reported that the number of ovarian relapses dramatically decreased in their cohort from the moment they introduced intermediate-dose methotrexate in the treatment regimen (from almost 10% of all relapses before 1979 to no ovarian relapse noted afterwards, until 1991). As they assumed,

isolated ovarian relapse has become an exceptional event, likely representing slightly less than 1% of all relapses [40,59]. However, contrary to testicular involvement, which can be clinically suspected with a simple physical examination, there is no overt clinical sign that allows suspicion of ovarian leukemic infiltration. In addition, ultrasound evaluation is not systematically performed during the course of the disease and follow-up, even if it might be [63]. However, it was possible to detect leukemic cells in up to 70% of samples by polymerase chain reaction of cryopreserved ovarian tissue retrieved at diagnosis (or shortly after), even in the absence of enlargement and with a negative histological examination (except in one patient from a study of Soares *et al.*, whose ovarian medulla was invaded) [64–67]. Most published studies concerning ovarian disease consist of case reports, which usually do not report the precise location of leukemic cells in the ovary [58]. In their autopsy series, Reid *et al.* found that leukemic invasion, which was mostly histologically mild, took place predominantly in the medulla in the perivascular spaces [57]. However, leukemic cells have also been detected in the cortex by other authors. Thus, it is difficult to say where the cells preferentially settle [64–67]. Nonetheless, follicles have never been reported to be invaded in the literature.

c) Central nervous system (Figure 2c)

Isolated CNS relapses represent approximately 7.5-15% of ALL relapse [3,8,38–41]. The precise location of leukemic cells in the CNS is rarely indicated in published studies. Autopsy and animal model studies have allowed a better understanding of how the CNS may be invaded by leukemic cells [68,69]. Indeed, Price and Johnson studied 126 brains from children who died of ALL and developed a grading system to evaluate the severity of arachnoid involvement. They detected leukemic cells in the CNS of 55% of patients. Most showed moderate leukemic infiltration and the authors observed that infiltration of the brain parenchyma occurred only in cases of extensive and deep leukemic arachnoid involvement

with cerebrospinal fluid (CSF) contamination and pia-glial membrane destruction (13.4% of cases). Arachnoid invasion was most often isolated or multifocal, rather than diffuse. They concluded that leukemic cells first invade the superficial arachnoid from the vein wall, then the deep perivascular arachnoid, and finally, the brain parenchyma through disrupted pia-glial membranes [68]. *In vivo* rodent models have provided similar results and suggest that leukemic cells transit through the blood-CSF barrier to reach the leptomeninges [69,70]. Although Price and Johnson only studied brain and did not consider the spinal cord or dura matter in their study, diffusion throughout the CNS *via* the CSF has been confirmed by leukemic cell DNA detection, both in the lumbar spinal cord and frontal brain of rats inoculated in the cerebellum [70]. This is consistent with neuroradiological findings, which indicate that meningeal infiltration is the most common manifestation of CNS leukemia, with most often diffuse infiltration [71,72]. However, although much rarer and mostly represented by case reports in the literature, CNS involvement may also consist of epidural masses that can compress the spinal cord [73]. Thus, leukemic cells do not colonize one specific anatomical region within the brain or other CNS sites, but rather appear to preferentially localize to the subarachnoid space, likely in perivascular areas. A very recent study, using a mouse model, has shown that meningeal invasion occurs through the diapedesis of leukemic cells from cranial or spinal bone marrow of adjacent bones. The authors reported that leukemic cells transit through blood vessels, the emissary vessels that bridge the CSF space from the brain or spinal cord to the calvarium or vertebral bodies. They also discovered that this mechanism involves an interaction between $\alpha 6$ integrin and laminin and that it can be blocked by specific PI3K δ inhibitors [74].

d) Others

Because leukemic cells spread throughout the organism via systemic circulation, other sites of relapse may be considered. Other extramedullary sites have been little studied and

published data consist mostly of case reports [75]. Although no site can be defined as privileged, since ALL can settle in many tissues, breast involvement may be a privileged site of extramedullary leukemia, mostly described by Isabel Cunningham [75–79].

2. Similarities between sanctuary sites

We chose not to provide an exhaustive comparison between metastatic niches but rather to focus on three representative common actors: the CXCL12/C-X-C chemokine receptor type 4 (CXCR4) axis, hypoxia, and stem cell factor (SCF).

a) The concept of “niche”

The BM microenvironment has been, and is still, extensively studied [80–84]. First postulated by Schofield in 1978, it is now accepted that hematopoietic stem cells (HSC) reside in specialized compartments, called “niches”, within the BM [85]. Such niches allow the maintenance and regulation of HSCs by providing specific local conditions, cytokines, chemokines, and other soluble factors, as well as various types of specialized stroma cells. Different types of HSC niches have been described in the literature and may be named differently, depending on the authors, which can be confusing [80,81,86,87]. Our understanding of the BM microenvironment is constantly evolving and is still a subject of debate. For example, some studies have provided evidence for the existence of an osteoblastic niche [86], but this has been more recently questioned. Indeed, the existence of an authentic osteoblastic HSC niche has been ruled out, even if osteoblastic lineage cells have an indirect role in the regulation of HSCs and appear to be part of a specialized niche for lymphoid progenitors [81,84]. Rather than viewing the BM as a suite of separated niches, it is more likely a unique continuous niche in which some components are shared (and some others not) between more specialized compartments within this niche, as proposed by Hira *et al.* [88].

268 HSCs localize mainly to perivascular zones, as do leukemic cells, with most found close to
269 sinusoids, whereas approximately 10% are found near small arterioles.

270 The microenvironments of the testes and CNS also have niches that maintain and
271 regulate spermatogonia and neural or glial stem cells, respectively[89–93]. It has been shown
272 in several cancer models that cancer cells can migrate from the tissue they originate to
273 predisposed distant niches, which they can then remodel to suit their needs [94,95]. Such
274 metastatic, BM, testicular, and neural niches may share characteristics that attract leukemic
275 cells and offer them a favorable microenvironment for maintenance and growth. We focus on
276 some of these shared components that have been found to play a major role in these
277 microenvironments.

278 ***b) CXCL12/CXCR4***

279 CXCL12, also known as stromal derived factor 1 alpha (SDF1 α), is one of the most
280 important chemokines in the BM niche [84]. Through binding to its receptor, CXCR4,
281 CXCL12 favors HSC homing to the BM and participates in the maintenance of these cells in
282 the niche. CXCR4 is a seven-transmembrane G-protein-coupled receptor that is expressed on
283 multiple cell types, including, notably, hematopoietic cells [96]. The inhibition of CXCR4 is
284 frequently used clinically to mobilize HSCs into the peripheral blood as a source of stem cells
285 for transplantation [84,97–99]. CXCL12 is highly expressed by specialized cells close to
286 sinusoid vessels within the BM, called CXCL12 abundant reticular cells , and favors HSC
287 retention in the BM [84,97].

288 CXCL12 has been shown to be involved in metastasis in many cancer models, such as
289 breast, prostate, and lung cancer, pancreatic adenocarcinoma, rhabdomyosarcoma, and others
290 [100]. For example, it was shown in an ovarian cancer model that the most advanced stages of
291 the disease and most invasive phenotypes are associated with increased CXCR4 expression at

292 the cancer cell surface. More importantly, ascites samples from patients with advanced
293 ovarian cancer showed significantly higher CXCL12 levels [101]. The role of the
294 CXCL12/CXCR4 axis in the dissemination of peritoneal cancer has been clarified more
295 recently in a study using a primarily murine colon cancer model. The authors found that
296 CXCL12-expressing cells, similar to CXCL12 abundant reticular cells and distributed
297 throughout the perivascular zones of adipose tissue, were a privileged site from which cancer
298 cells could disseminate [102]. In another example, Ogawa *et al.* showed that CXCL12
299 expression increased in the regional lymph nodes of mice with intrapulmonary transplanted
300 cancer cells in a Lewis lung carcinoma model, and participated in the formation of a pre-
301 metastatic niche [103].

302 The CXCL12-CXCR4 axis is also involved in the pathogenesis of leukemia, as it favors
303 not only ALL cell homing in the BM, but also their survival and proliferation [42,43,104,105].
304 Some evidence indicates that, in the human testis, CXCL12 is expressed solely by Sertoli
305 cells to promote spermatogonial stem-cell migration through the seminiferous tubules during
306 spermatogenesis [106–109]. Sertoli cells reside in seminiferous tubules, where leukemic cells
307 are generally not found, or only very late during testicular involvement. However, the use of
308 transwell migration assays showed that ALL cells can also migrate towards mouse testis
309 conditioned medium and that such migration was reduced when the cells were treated with
310 plerixafor, a CXCR4 chemical inhibitor [110]. This result suggests that leukemic-cell
311 migration towards the testis might be at least partially mediated (or not exclusively) by the
312 CXCL12/CXCR4 axis. Moreover, McIver *et al.* have shown that although CXCL12
313 expression is restricted to Sertoli cells in the normal testis, it is expressed in the tumor stroma
314 of seminoma samples [107]. Pathological conditions may induce CXCL12 expression in the
315 interstitium of the testis [111]. Thus, it is possible that leukemic cells could be attracted and
316 settle in the testis.

317 The CXCL12/CXCR4 axis is also known to play an important role in neurogenesis and
318 neuron migration during development [112–116] and CXCL12 is constitutively expressed in
319 the adult CNS, where it participates in neuromodulatory functions and acts as a major player
320 in neuro-inflammation by recruiting leukocytes across the blood-brain barrier [112,117–120].
321 McCandless *et al.* showed that normal expression of CXCL12 on the basolateral side (*i.e.*
322 away from vessel lumen) of CNS endothelial cells retains leukocytes in the perivascular
323 space, thus preventing their egress to the CNS parenchyma [119,120]. Leukemic cells may
324 therefore be attracted into perivascular areas by such a CXCL12 expression pattern, where
325 they could stay, possibly in a quiescent state. Indeed, recent studies in a T-ALL model have
326 shown that the CXCL12/CXCR4 axis plays an important role in leukemic-cell migration into
327 the CNS [121,122]. Nevertheless, although treating xenografted mice with plerixafor (a
328 CXCR4 antagonist) reduced engraftment into the BM and liver in a B-ALL model, it failed to
329 prevent blast infiltration of the CNS, suggesting that CNS infiltration may not be mediated by
330 the CXCL12/CXCR4 axis in B-ALL [69]. Other studies indicate that the CXCL12/CXCR4
331 axis is also involved in leukemic-cell infiltration into other extramedullary tissues. Indeed,
332 Crazzolaro *et al.* found that high CXCR4 expression at the surface of ALL cells was
333 associated with more pronounced infiltration of extramedullary tissues, such as liver and
334 spleen, which was confirmed later in another study using a NOD/SCID immunodeficient
335 mouse model [123,124]. Consistent with the latter studies, Kato *et al.* demonstrated that the
336 liver constitutes a favorable niche promoting ALL cell engraftment, survival, and
337 chemoresistance through the CXCL12/CXCR4 axis [125]. Overall, there is evidence in the
338 literature showing that the CXCL12/CXCR4 axis plays a major role in ALL cell homing, both
339 to the BM and extramedullary niches. Thus, CXCL12 represents a common feature of
340 hematopoietic, extramedullary, and solid tumor niches, which may reconcile ALL and solid
341 tumor models.

c) Oxygen content

Improperly termed hypoxia, low oxygen concentrations are physiologically found in specific areas in mammalian organisms [126]. Indeed, the BM is likely to be one of the tissues in which the oxygen concentration is the lowest [127]. Ishikawa and Ito measured oxygen tension in BM samples from 4.9% to 8.8%, but it likely poorly reflects the true oxygen level found in the BM [128]. Later, mathematical modeling predicted the existence of an oxygen gradient in the BM, with oxygen tension decreasing progressively, starting from the sinus [129,130]. Since then, experimental evidence has confirmed very low oxygen concentrations in the BM, with the lowest value measured at 0.6% [131,132]. Increasing evidence suggests that the niches in which HSCs reside are hypoxic and that low oxygen concentrations may be needed to maintain their stemness [132–137].

Low oxygen concentrations have been highlighted during cancerogenesis in solid tumors. As reviewed elsewhere, hypoxia in cancer cells and in the tumor microenvironment promotes aberrant angiogenesis, epithelial-mesenchymal transition, radio- and chemoresistance, and metastasis [138]. For example, it has recently been shown in a breast cancer model that hypoxia can upregulate pro-metastatic genes and promote metastasis, particularly under conditions of intermittent hypoxia, [139]. Moreover, the authors found that breast-cancer cells cultured under hypoxic conditions secreted pro-tumorigenic cytokines. Hypoxia was similarly shown to enhance the invasiveness of melanoma cell lines *in vitro* and promote metastasis *in vivo* [140].

More importantly, low oxygen concentrations are thought to be an important component of leukemic niches in the BM and recent results have shown that targeting this hypoxic microenvironment may be promising [141–148]. Indeed, hypoxia has been shown to enhance the chemoresistance of ALL cells and appears to confer stem-cell properties, such as

quiescence [141,149,150]. Drugs active only under conditions of hypoxia were shown to reduce the leukemia burden in the BM when administrated three days after ALL cell injection into NOD/SCID mice, suggesting that hypoxia may favor leukemic-cell engraftment [141,147].

The testes are also thought to be one of the most hypoxic tissues. Direct measurements in a rat model established the interstitial testicular oxygen concentration between 1.5 and 3.5% [151,152]. Another study using pimonidazole staining, commonly used as a hypoxic marker, confirmed these results in a mouse model and suggested an even lower intratesticular oxygen tension, especially in the seminiferous tubules, as well as the interstitium [153]. Nevertheless, there is no evidence of an association between the hypoxic features of the testis and testicular leukemia infiltration as it has not been directly studied.

Low oxygen concentrations are also found in the CNS, from 0.5% to 7%, both in humans and animal models [126]. There are few clues in the literature to estimate the oxygen tension of subarachnoidal tissue, where ALL cells preferentially settle. Some studies have evaluated the oxygen tension within the CSF, with estimated values of approximately 5 to 6% [154,155]. More recently, Sharan *et al.* showed that oxygen tension decreases rapidly from pial vessels to the extravascular space in a rodent model, with oxygen levels as low as 3% 30 μ M from the vessels, especially the narrowest ones [156]. Thus, although oxygen concentrations have not been precisely measured in the subarachnoidal space, they are likely to be low. Recent published data have indeed suggested a role for low oxygen concentrations in leukemic cell CNS infiltration [157,158]. In these two independent studies, the authors found that leukemic cells retrieved from the CNS of xenografted mice had a hypoxia-related gene set profile and expressed a particularly high level of the transcript of the vascular endothelial growth factor A (VEGFA) gene, which is a principal target of the hypoxia master transcription factor, hypoxia inducible factor 1 (HIF1). More importantly, Münch *et al.* further

showed that VEGFA mediated the migration of ALL cells through a monolayer of a brain-microvasculature cell line [158]. The results from these studies are in accordance with those of a previous one showing that patients with CNS leukemia had elevated levels of VEGF in the CSF [159]. Thus, the role of hypoxia in extramedullary leukemia merits exploration and may offer new therapeutic perspectives, as outlined by Izraeli and Eckert [160].

d) Stem cell factor

Stem cell factor (SCF), also known as steel factor or mast cell growth factor, is one of the main growth factors that regulate the proliferation and survival of HSCs and hematopoietic progenitors in the BM, through binding to its receptor, c-KIT [161–163]. Indeed, insertion of the *Egfp* gene into the endogenous locus of the *Scf* gene in C57BL mice results in perinatal death with severe anemia. GFP expression patterns within the BM have suggested that SCF is produced in the BM by perivascular stromal and endothelial cells, which was further demonstrated using a conditional deletion model in the same mice [164]. Moreover, Ding *et al.* demonstrated that SCF is necessary to maintain adult HSCs, using the same conditional deletion model. Along with its effects on progenitor cell survival and proliferation, SCF has also been shown to have a chemotactic function in these cells [162]. Proteolytic cleavage and alternative splicing lead to various tissue-specific isoforms of SCF, which can be produced as soluble or membrane-bound forms [161–163,165,166]. The membrane-bound form of SCF appears to be essential [162]. The membrane-bound form of SCF has notably been shown to enhance human HSC engraftment in murine xenografts. It has also been shown to promote cell adhesion *in vitro* and HSC residence in the BM niche *in vivo* [162,167–169].

In solid tumors, SCF/c-KIT signaling is also frequently thought to participate in tumorigenesis, tumor progression, and metastasis. Soluble SCF is produced by cancer cells

within tumor tissues in different cancer models [170]. c-KIT has been found to be overexpressed, abnormally expressed, or associated with an aggressive phenotype in several types of tumors, including melanoma, lung cancer, renal carcinoma, and seminoma [163,171,172]. Activating mutations of c-KIT can be found in some tumor types, especially gastrointestinal stromal tumors, and may be involved in their pathogenesis. The SCF/c-KIT pathway may also be involved in the pathogenesis of such tumors through its effect on mast cells [163] and the mast cell accumulation has been associated with a worse prognosis in several cancer models.

The SCF/c-KIT signaling pathway has also been found to be deregulated mostly in AML models rather than in ALL models. However, although c-KIT is little expressed in ALL relative to AML, RNA-seq data indicate that some ALLs overexpress c-KIT, such as ETS variant 6-runt related transcription factor 1 (ETV6-RUNX1) B-ALL or mixed lineage leukemia (MLL) rearranged leukemias [173]. Consistent with the expression of c-KIT in these malignancies, SCF participates in early B-cell development in association with interleukin-7 (IL7) [161]. Moreover, it was shown that ALL cells can modify their microenvironment by producing SCF [43]. Thus, the involvement of SCF signaling in the homing and pathophysiology of ALL may merit exploration, as suggested by a recent report [174].

The SCF/c-KIT axis plays also an important role in male reproduction, as suggested by the infertility of mice with mutations affecting both the *W* (encoding c-KIT) or *Sl* (encoding SCF) loci [161,163]. In the testis, SCF is produced by Sertoli cells and c-KIT is expressed on the surface of germ cells and Leydig cells, raising the possibility that Sertoli cells secrete a soluble form of SCF [171,175,176]. Indeed, a higher percentage of mRNA for the soluble than membrane form of SCF correlated with higher serum testosterone levels in infertile patients [177]. These results suggest that Sertoli cells may produce soluble SCF that reaches Leydig cells and thus enhance testosterone production. Moreover, SCF expression in normal

adult interstitial testicular tissue has been reported both in mice and humans in several immunohistochemistry studies, even if several others did not [178–181]. Thus, leukemia cells may be attracted to or retained in testicular interstitial tissue at least partially through activation of the SCF/c-KIT pathway.

SCF is also expressed in the adult CNS, as well as in CSF, and is involved in CNS development during embryogenesis [182–184]. There is no direct evidence in the literature for a role of the SCF/c-KIT axis in the attraction of leukemia cells to the CNS or their subsequent survival. However, SCF is one of the specific cytokines expressed by endothelial cells of the blood-brain barrier [183]. Kallman *et al.* compared gene expression profiles of human umbilical vein endothelial cells (HUVEC) and primary human cerebral endothelial cells using a cDNA array technique and found that 35 genes were differentially expressed in cerebral endothelial cells, including those for interleukin-6 (*IL-6*), transforming growth factor β 2 (*TGF- β 2*), *VEGFA*, and *SCF* [183]. An enzyme-linked immunosorbent assay (ELISA) confirmed that the supernatant from these cells contained SCF. Thus, endothelial cells of the CNS can produce SCF that may attract and/or promote the survival of leukemia cells that express c-KIT.

Overall, these examples suggest that the SCF/c-KIT axis may be an attractive therapeutic target for leukemia relapse, both at medullary and extramedullary sites, as well as for various solid tumors.

d) Other shared factors

The extracellular matrix protein osteopontin, which is physiologically produced in the BM, participates in the pathophysiology of various cancers, including hematological malignancies, with a potential role in leukemic cell CNS infiltration [185,186]. Colony stimulating factor 1 (CSF1), a cytokine involved in macrophage differentiation and

464 constitutively expressed by osteoblasts, is expressed in prepubertal and adult testicular
465 interstitial tissue, notably by macrophages, and has a role in regulating spermatogonial stem
466 cells and their niche[187–189]. CSF1 is also expressed in the CNS, where it maintains
467 microglia and participates in CNS development [190]. CSF1 deficiency impairs both
468 reproductive function and integrity of the CNS. Genetic alterations involving the CSF1
469 receptor, including the recurrent SSBP2-CSF1R fusion, have been identified in B-ALL and
470 have been found to lead to a functional fusion, suggesting that targeting CSF1 signaling could
471 be promising [191–193]. Another cytokine, transforming growth factor β 1 (TGF β 1), regulates
472 Leydig cell function in the testis, but is also secreted by the choroid plexus in the CSF, where
473 it contributes to the maintenance of the choroid plexus itself and appears to be involved in the
474 protection and repair of nervous tissue. TGF β 1 has been shown to be involved in cancer
475 stemness, metastasis, and epithelial-mesenchymal transition in several cancer models.
476 Recently, TGF β 1 was found to promote the escape of leukemic cells from natural killer (NK)
477 immune surveillance in an ALL model.

478 All these factors and other components, such as the various cell types found within the
479 niche, may also contribute to therapy resistance by preventing treatments from reaching their
480 targets. BM and extramedullary sites may therefore contain pharmacological niches, where
481 leukemic cells are protected from the effects of chemotherapy. For example, mesenchymal
482 stem cells have been shown to participate in the resistance of leukemic cells to asparaginase
483 treatment by providing them with asparagine [194]. Interestingly, it was further found that
484 vincristine treatment administered prior to asparaginase can affect mesenchymal cells, thus
485 blocking the secretion of asparagine and overcoming this resistance mechanism [195]. This
486 indicates that treatments may exert their effect not only by affecting leukemic cells but also
487 their microenvironment.

We have shown that leukemic cells, like other cancer cells, exploit several identical features of the microenvironment to reach distant sites. We now discuss whether blast cells may prepare their distant niches for engraftment and proliferation.

IV. The interplay between leukemic cells and the microenvironment

1. Leukemic and cancer cells model their niche

More than one century ago, Stephen Paget noted that breast cancer metastases occur more often in some tissues than others and, refuting that this could hardly occur by chance or solely by embolism, formulated his famous “seed and soil” hypothesis [196]. He compared cancer cells to plant seeds that can only grow in favorable soil, that is, in a tissue somewhat predisposed to welcome them. At that time, he already recognized that not only cancer cells but also their “soil” would be worth studying. Since then, a large amount of information has accumulated on cancer cell biology and the organotropism phenomenon has been experimentally explored and demonstrated [197,198]. We illustrated above that some leukemic cells, like some cancer cells, may be prone to home to and remain in certain microenvironments that resemble that from which they originated. However, such a remote and different microenvironment will not perfectly match the original niche and will probably not meet all the needs of the leukemic cells.

Indeed, there is evidence that leukemic cells can remodel their microenvironment [199]. Colmone *et al.* used an *in vivo* microscopy imaging approach and found that ALL cells remodeled the BM microenvironment they colonized, notably through SCF signaling, leading to an abnormal niche that recruited and somehow trapped normal hematopoietic progenitors [43]. More recently, Boyerinas *et al.* xenografted the leukemic Nalm6 cell line in a mouse model and showed that the leukemic cells secreted osteopontin into the invaded microenvironment, which in turn also produced osteopontin [200]. It was also shown using *ex*

vivo co-cultures of primary mesenchymal stromal cells and either the Nalm6 cell line or primary ALL cells that although the CXCL12/CXCR4 axis was involved in leukemic cell migration, other chemokines, such as C-C motif chemokine ligand 2 (CCL2) and CXCL8 may be involved in leukemic niche formation, independently of the CXCL12/CXCR4 axis. Transwell assays also demonstrated that leukemic cells could recruit mesenchymal stromal cells to initiate the leukemic niche, in which secreted chemokines might attract other leukemic cells while inhibiting that of healthy hematopoietic progenitors and mesenchymal stromal cells [201]. These results are consistent with those of other studies including that of Colmone *et al.* in which Nalm6 cells colonized CXCL12 niches in the BM of xenografted mice, which subsequently resulted in marked downregulation [43,202]. A recent report showed that leukemic cells can promote osteoclast-mediated bone resorption through the production of receptor activator of nuclear factor κ B ligand (RANKL) [203]. This is in accordance with a previous report that demonstrated in a T-ALL mouse model that ALL cell engraftment in the BM of mice was associated with bone microenvironment remodeling due to a marked loss of osteoblastic cells [204]. Duan *et al.* used *ex vivo* imaging of xenografted mice to confirm that engrafting ALL cells alters the BM microenvironment, resulting in damage to the vasculature and endosteal lining. This report also showed that, following chemotherapy, leukemic cells secreted cytokines, namely CCL3 and TGF β , inducing phenotypic changes in the surrounding mesenchymal stem cells. These cells provided a protective microenvironment for the leukemic cells by converting a growth differentiation factor 15 (GDF-15) proform secreted by the leukemic cells into a mature form, which led to the activation of TGF β signaling, thereby conferring chemoresistance [44].

Recent studies on solid tumors have led to a better understanding of cancer-cell organotropism and metastatic niche formation. Kaplan *et al.* first demonstrated, in 2005, that cancer cells can remotely prepare an appropriate niche before reaching their metastatic site

[198,205]. The authors demonstrated that cancer cells secrete certain factors that may predispose them to metastasize toward a specific location. They first suggested cytokines, but discovered several years later that the cancer cells produced exosomes that could direct metastatic cancer cells to specific tissues [198,206]. Exosomes are small extracellular vesicles (30-100 nm of diameter) that can be transferred to other distant cells to deliver functional molecules, such as peptides or nucleic acids. Thus, exosomes are a means of intercellular communication suitable for remote cells. Exosomes derived from different cancer cell lines specifically target different tissues. An elegant experiment showed that exosomes can “educate” cancer cells to reach a specific tissue. Mice were injected with exosomes from cells that usually metastasize to the lungs before being transplanted with cells that do not usually metastasize to the lungs, but to bones. This experiment resulted in a large significant increase in lung metastases. Going further, the authors found that exosomal organotropism was determined by their integrins, which allowed exosome uptake by specific tissue-resident stromal cells within target tissues. Exosome uptake by these cells was followed by upregulation of the expression of *S100* family pro-migratory and pro-inflammatory genes, which could favor tumor metastasis. Importantly, specific exosomal integrins recovered from plasma samples of patients with pancreatic or breast cancer correlated with the location of the metastases, and may even likely predict future metastatic sites at the time diagnosis.

2. Means of communication between ALL cells and supportive cells

Several means of communication are available to ALL cells to interact and communicate with their surrounding microenvironment and they may be used simultaneously. The role of exosomes in the pathophysiology of several cancers is becoming increasingly understood but has been little studied, to date, in the context of ALL [83,207]. However, recent findings have shown that large extracellular vesicles (EVs), released through plasma membrane budding, may be of particular importance for the communication between ALL

cells and their microenvironment [208,209]. Indeed, the group of Vaskar Saha showed that ALL cells can produce EVs of varying size, some of which could be transferred horizontally to other ALL cells, as well as BM stromal cells, resulting in phenotypic changes in the recipient cells [209]. The transfer of large EVs to BM stromal cells induced a metabolic change, favoring glycolysis in these cells, which increased the lactate concentration in the medium, thereby providing the leukemic cells with their preferred fuel, as hypothesized by the authors [208]. These large EVs were released into the systemic circulation of xenografted mice. It is thus possible that EVs participate in similar metabolic reprogramming and/or other phenotypic changes in remote stromal cells to promote ALL-cell migration to the secondary sites. Although more compelling evidence has yet to be provided, it seems likely that both exosomes and large EVs are involved in preparing a remote suitable niche for ALL cells. In addition, large EVs may also contain intact organelles that could be transferred to recipient cells [209]. Not all cells can generate EVs. Thus, as discussed by the authors, such mechanisms may allow EV-producing resistant leukemic cells to promote chemoresistance, or even resistance to targeted therapies, by transferring pro-resistant cellular content to other sensitive cells.

The transfer of organelles, such as mitochondria, could also allow recipient cells to cope with acute stress [210]. Another recent study showed that ALL cells also communicate with mesenchymal stromal cells using tunneling nanotubes to set up their niche [211]. Tunneling nanotubes are thin plasma membrane protrusions that connect one cell to another and allow the exchange of cellular content. This means of intercellular communication is independent of others and can promote leukemic cell survival, chemoresistance, and the release of cytokines into the microenvironment. The use of fluorescent dyes has made it possible to visualize the exchange of cellular content in both directions, from leukemic cells to mesenchymal stromal

cells and *vice versa*, confirming that ALL cells establish crosstalk with the surrounding microenvironment to protect themselves and promote their survival [211].

Direct contact of leukemic cells with stromal cells has also been previously highlighted in the pathogenesis of leukemia. Indeed, direct contact with stromal cells favors ALL cell survival, offers them a protective environment, and may minimize the effects of cytotoxic drugs [212–215]. Such cell-cell contact was found to be mediated, notably, by the binding of integrin $\alpha 4\beta 1$, also called very late antigen-4 (VLA4), expressed on the surface of ALL cells, to the vascular adhesion molecule-1 (VCAM1), expressed on the stromal cell surface [216]. Integrin $\alpha 4\beta 1$ can also bind to extracellular matrix proteins, such as osteopontin and fibronectin, and has been shown to play an important role in ALL cell homing in mice [200,217,218]. In addition to its role in adhesion to extracellular matrix and/or stroma, it is likely that integrin $\alpha 4\beta 1$ binding to its receptor induces signaling cascades to promote leukemic cell survival, proliferation, and/or chemoresistance [218]. Gap junctions are also involved in cell-cell interactions within the leukemic niche. Gap junctions allow the direct exchange of small molecules between two adjacent cells by creating a channel, most often through the alignment and docking of two connexons (consisting of hexamers of specialized proteins called connexins) of each cell. Several studies have suggested that leukemic cells can communicate with stromal cells through gap junctions formed with connexin 43 (Cx43) [219–223]. Although the mechanisms are still unclear, it appears that Cx43 gap junctions are dysregulated in leukemic BM. Another connexin, Cx25, has recently been thought to be involved in the pathogenesis of leukemia through gap junctions [224]. The authors showed, using both T-ALL and AML cells, that inhibiting gap junctions by selective Cx25 knockdown sensitized the cells to chemotherapy, suggesting that concomitant Cx25-targeted treatment could allow reducing the dose of cytotoxic agents in clinical practice, thereby reducing the side effects of chemotherapy while conserving its efficacy [224].

Direct communication of leukemic cells with the surrounding supportive cells, probably as well as distant communication from the original to the secondary niche, appears to be of crucial importance. Once in the secondary niche, leukemic cells must deal with the local cells, which must be suitable surrogates that sufficiently resemble BM stromal cells. In the CNS, for example, Akers *et al.* found, *in vitro*, that ALL cell lines were attracted to astrocytes, choroid plexus epithelial cells, and even more strongly to meningeal cells, to which they could strongly adhere. The authors showed that these cells from the CNS secreted amounts of CXCL12 equivalent to those of BM stromal cells and osteoblasts and that CXCR4 blockade with plerixafor could inhibit ALL cell migration toward meningeal and plexus choroid epithelial cells. They also observed that co-culture of both ALL cell lines and primary ALL cells with any of these CNS cells decreased the effects of commonly used chemotherapy drugs on leukemic cell viability. The provided chemoprotection was likely the result of the combined effects of soluble factors and cell-cell contacts between the ALL cells and the CNS cells [225]. This study illustrates that ALL cells can interact with supportive cells other than those which belong to the niche from which they originate. Such cells may therefore be similar to those of the BM niche and ALL cells can communicate with them to enhance their leukemic-supportive properties and adapt themselves to better settle into secondary niches.

The interconnections involved in this interplay are complex, but the methods used in studies usually only focus on one aspect of one component of the leukemic microenvironment. For example, cell-cell interactions have mostly been studied through co-culture systems consisting of only leukemic cells and one type of stromal cell, although leukemic cells probably interact not only with supportive stromal cells but also other cells within the microenvironment. Similarly, hypoxia can induce CXCL12 and CXCR4 expression, as well as that of SCF, and SCF itself has been found to increase HIF1 α expression [226]. Leukemic cells may escape the effects of therapy by taking advantage of

636 this system, of which the complexity is even more pronounced if we consider other
637 parameters, such as temporality.

638 3. The chicken or the egg causality dilemma in ALL relapses

639 An intriguing question is whether the cells found far from their original niche are the
640 result of the development of a resistant clone that reached its secondary niche in response to
641 treatment, or whether these cells were already there as leukemic or preleukemic clones, even
642 before diagnosis. Recently, Williams *et al.* addressed this question in the context of B-ALL
643 and found that most leukemic cells had the capacity to infiltrate the CNS and were not
644 restricted to a specific population [69]. They demonstrated, in clonal tracking experiments,
645 that the populations engrafting the CNS were polyclonal, and that the clones found in the
646 CNS were also found in the spleen or BM of xenografted mice. The authors concluded that
647 CNS invasion is a “generic” capacity of leukemic cells but, as they also discussed, their
648 results do not rule out the possibility of the existence of specific clones particularly well-
649 adapted for invading the CNS microenvironment and surviving there. They also did not
650 discuss whether the cells already possessed this capacity to invade the CNS at a preleukemic
651 stage. Also, one cannot exclude that a leukemic cell may have been generated during
652 embryonic or fetal hematopoiesis and would stay in a dormant state in the CNS.

653 Similarly, solid tumor cells can settle at tissues distant from their original site early
654 during the course of the disease, even before detection of the primary tumor [227,228]. Solid
655 cancers, as well as leukemia, must be viewed as a systemic disease, in which cancer cells
656 spread and engraft early at predisposed tissues that provide protection against insults, such as
657 chemotherapy, notably through the induction and maintenance of a dormant state [227,229].
658 However, as metastasis is an inefficient process, only a few cells may have the ability to
659 survive and grow out of their original niche [230]. Such rare cells would be able to adapt

660 themselves to a new microenvironment, where they could become quiescent or grow slowly,
661 explaining why some patients experience very late relapses in distant tissues. The existence of
662 leukemic stems cells (LSCs) that would be responsible for late relapses may also be evoked.
663 However, these LSCs are not well characterized, especially in B-ALL, and several reports
664 indicate that ALL cells with the capacity to initiate leukemia are relatively frequent [231, Le
665 viseur 2008]. We have therefore chosen to focus on the role of the microenvironment, which
666 appears to play an important part in the leukemia-initiating ability of ALL cells.

667 Ebinger *et al.* recently used an ingenious cell labeling system in patient-derived
668 xenografts to provide evidence that such dormant cells exist in ALL and provided a robust
669 preclinical model [45]. The authors found that these dormant cells shared a similar
670 transcriptional program with leukemic cells found at MRD level in patients. Moreover, these
671 dormant cells were resistant to conventional chemotherapy *in vivo*, but became sensitive to
672 drugs when retrieved from their microenvironment and treated *ex vivo* [45]. This result has
673 two principal clinically relevant implications: first, the dormant phenotype that appears to be
674 harbored by MRD cells is reversible and second, the microenvironment appears to play a
675 critical role, strongly suggesting that targeting the microenvironment could be a promising
676 strategy to kill the disease and prevent relapse and treatment failure. As the authors state, it
677 may also explain why children treated for ALL benefit from standard maintenance therapy
678 that continues for two years from diagnosis: daily doses of low-dose chemotherapy might help
679 to progressively eradicate all ALL cells, including the dormant cells that may reenter the cell
680 cycle after the intensive phase of treatment. Although the authors showed that dormant ALL
681 cells were preferentially found close to the BM endosteum, they did not explore engraftment
682 in other tissues. It would be informative to use their model to verify whether such dormant
683 cells can also be found in the extramedullary tissues frequently invaded in clinical practice,
684 especially the perivascular areas described above. This study also argues in favor of an

extramedullary origin for combined ALL relapses, especially late relapses [59], as the dormant ALL cells were shown to have leukemia-initiating properties.

V. From bench to bedside

Leukemic cells interact dynamically with their microenvironment. Indeed, intravital microscopy experiments, which allowed the high-resolution observation of leukemic cells in live animals, showed the leukemic cells to be motile without any objective preference for a specific location or supportive cells [204]. Treatment of the mice with drugs commonly used in clinical practice (vincristine, dexamethasone, and asparaginase) reduced the leukemic burden and induced an increase in the proportion of quiescent cells, but did not modify the patterns of cell distribution and the cells kept moving, even faster than those of untreated mice [204]. These results suggest that leukemic engraftment was randomly driven, in contrast with other reports and commonly held beliefs. Thus, as stated by Williams *et al.*, engraftment potential may not be restricted to a specific cell population but may be shared by most ALL cells. This was recently corroborated by two independent studies [69,231,232]. In these studies, the authors used a cellular barcoding strategy to track leukemic clone engraftment in the BM of different bones and several extramedullary tissues of xenografted mice [231,232]. Both studies showed that the engrafting cell populations were polyclonal, similarly to solid tumors, suggesting that all founder cells were able to reconstitute a leukemic bulk population. However, the authors found that the clonal distribution differed depending on the tissues analyzed: a clone could be more highly represented in one tissue, whereas another could be predominant in another tissue. The authors stated that this asymmetric clonal distribution was presumably stochastic and probably not due to clonal preference or a predisposition to settle in one site over another. As the authors discussed, the specific microenvironment may confer an advantage to arriving leukemic cells that favors settlement and/or the proliferation, explaining the observed asymmetric distribution. Notwithstanding the evidence provided by

710 the intravital microscopy experiment of Hawkins *et al.*, some cells from the founder
711 population exposed to such a niche may become quiescent and be the ancestor of a subsequent
712 relapse [204].

713 Aside from these studies, there is evidence in the literature suggesting that leukemic
714 cells could themselves carry specific features that may direct their engraftment to one or
715 another tissue. Van der Velden *et al.* recently identified a protein profile that could potentially
716 help predict CNS relapse at the initial diagnosis. A comparison of the gene expression profiles
717 between leukemic cells from the BM and CNS of patients allowed the identification of genes
718 differentially expressed by leukemic cells from the CNS. Among these genes, *SSP1* (coding
719 for osteopontin) and *SCD* (coding for stearyl-CoA desaturase) were found to be upregulated,
720 which was further confirmed both at the mRNA and protein levels. Retrospective flow
721 cytometry analysis of BM samples from patients who experienced a CNS relapse showed that
722 both SPP1 and SCD proteins were elevated in a small subpopulation of cells, suggesting that
723 this expression profile might be used in a clinical setting to predict CNS relapse [233]. As
724 Frishman-Levy and Izraeli discussed in a recent review, in which they summarized current
725 knowledge concerning CNS leukemia, the contradictory nature of these results with those of
726 Williams *et al.* could be partially explained by methodological discrepancies (mouse
727 xenograft model *versus* a human model). The idea that CNS tropism may be linked to a
728 specific ALL population is also supported by the association of several recurrent genetic
729 alterations with the incidence of CNS relapse. Indeed, the chromosomal rearrangement
730 t(1;19), leading to the *TCF3-PBX1* fusion transcript, has been associated with an increased
731 risk of ALL relapse in the CNS [234,235]. This clinical finding has recently been supported
732 by a biological explanation. It was shown that primary leukemic cells expressing the *TCF3-*
733 *PBX1* transcript expressed high levels of Mer tyrosine kinase, for which the signaling

pathway was further shown to be involved in ALL cell survival and chemoresistance in the CNS microenvironment [236].

Leukemia with the t(12;21) chromosomal rearrangement, which leads to the ETV6-RUNX1 fusion protein, is associated with an increased risk of testicular relapse [4]. We previously compared the expression profiles of ETV6-RUNX1 with those of other B-ALL and found that fourteen genes were differentially expressed in this type of leukemia [237]. Among these genes, *CD9* (tetraspanin) was found to be underexpressed, which was further confirmed by flow cytometry of patient samples [238]. We reasoned that CD9 may be involved in the pathogenesis of this particular B-ALL subtype [239]. We found that CD9 has a role in leukemic cell dissemination through the Ras-related C3 botulinum toxin substrate 1 (RAC1) signaling pathway. Importantly, we showed that the more CD9 was expressed at the surface of ALL cells, the more cells were able to migrate into the testes in a mouse xenograft model [110]. Thus, ETV6-RUNX1 ALL relapses may be partially explained by enhanced CD9 expression, which favors blast dissemination and engraftment into the testis.

We postulate that ALL relapses occurring at specific sites could be explained by the association of both extrinsic and intrinsic factors, thus reconciling biological and clinical research findings. Specific genetic alterations may modify cell signaling pathways that could render the cells stochastically exposed to a specific microenvironment to take advantage of it and durably settle in it.

The role of the microenvironment in the pathogenesis of ALL has also been suggested by the good results obtained by treating or preventing extramedullary relapses with specifically directed local treatments. Indeed, aside from the introduction of high-dose methotrexate or aracytine, successful treatment of testicular or meningeal involvement has been specifically directed at the tumor: surgery/radiation therapy for the testis and intrathecal chemotherapy or radiation therapy for the meninges. This may explain the relatively good

prognosis for relapses at these sites and is another argument for an important role of the microenvironment, which is removed by surgery and radiotherapy. The role of the intrinsic properties of leukemic cells concerning their interaction with their surrounding microenvironment may be illustrated by the worse prognosis seen in Ph-like and Ph⁺ B-ALLs. Ph⁺ B-ALL and Ph-like B-ALLs share similar genetic alterations and a poor response to chemotherapy relative to other B-ALL subtypes. Within these subtypes, alteration of the Ikaros gene is frequently found. This alteration was shown to alter the adhesive properties of leukemic cells and may influence their settlement in their niche.[240].

VI. Therapeutic challenges

Therapeutic efforts in the past 15 years have mainly focused on the development of new molecules and immunological approaches directed against specific targets expressed on leukemic cells. Treatment intensification in patients with the most unfavorable prognostic factors has not only improved their survival, but also allowed to efficiently treat extramedullary leukemia without using local treatments. As mentioned earlier, the use of high doses of certain drugs, such as methotrexate, reduced the incidence of extramedullary involvement. Apart from these leukemic cell-oriented targeted therapies, therapeutic strategies oriented toward leukemic niches are also attracting increasing interest [241]. Figure 3 illustrates a few examples of strategies that could be used to target leukemic cells in their microenvironment and Table 1 shows several examples of molecules that could be used or tested in clinical practice during the coming years. These strategies may also be applied to reach cancer cells in solid tumor metastatic niches.

First, preventing cell migration and engraftment into the niche or, conversely, the mobilization of niched cells could be attempted, for example by disruption of the CXCL12/CXCR4 axis using CXCR4 inhibitors, such as plerixafor [105,124,242,243].

783 Targeting cell adhesion to the extracellular matrix or supportive cells may also be a useful
784 strategy, for example, by inhibiting $\alpha 4\beta 1$ integrin-mediated adhesion with a specific
785 monoclonal antibody, such as natalizumab, or a chemical inhibitor, such as TCB3486
786 [244,245]. Another possible niche-oriented therapeutic strategy could be to target integrins,
787 since exosomes home to future metastatic sites via integrins in melanoma and lung cancer
788 models. Directly targeting integrins could thus interrupt cellular communication with the
789 secondary niches [206]. Targeting niche features may also be a beneficial strategy, for
790 example by using hypoxia-activated prodrugs, such as PR104 and TH-302 [141,145–
791 147,246]. In ALL, modifying the leukemic microenvironment to reverse the phenotype of
792 dormant blast cells could be also a viable option [45]. This could be achieved by restoring a
793 healthy microenvironment, for example by using bisphosphonates that could prevent bone
794 degradation, which is observed in leukemia pathogenesis [203,204]. Another possible strategy
795 could target signaling pathways that are upregulated upon the interaction of malignant cells
796 with their microenvironment, such as the TGF β and HIF1 α pathways, for which several
797 preclinical or early clinical studies have been published [246,247]. The immune system could
798 also be manipulated, as seen in Hodgkin lymphoma, a hematological malignancy with a rich
799 microenvironment, with impressive results from recent early clinical trials testing specific
800 anti-programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) antibodies [248,249].

801 Many challenges have yet to be addressed concerning these and other strategies that
802 could target malignant cells in their niches in hematological and solid cancers. Given the
803 complexity of the microenvironment, successful treatment will probably require a
804 combinatory approach, by associating these therapies both between themselves and with
805 conventional chemotherapies. It is likely that such treatments would exert their full potential
806 by adding them to chemotherapy after the initial diagnosis to prevent the occurrence of

807 relapse. They should probably be reserved for refractory patients or those with the highest risk
808 of relapse.

809 **VII. Conclusion and future directions**

810 Leukemic niches and their interplay with leukemic cells are of tremendous complexity,
811 for which we have only limited information. The aim of this review was to illustrate this
812 concept by giving a few examples, rather than being exhaustive, to describe potential niche-
813 targeted therapeutic strategies that could be considered in the near future. We chose to
814 consider leukemia relapses like solid tumor metastases. We described several features of the
815 microenvironments of medullary, extramedullary, and metastatic niches, focusing on their
816 similarities, suggesting that ALL relapses might be considered more like leukemic metastases.
817 We provide lines of evidence showing that ALL cells, as well as other cancer cells, can
818 communicate with and remodel their microenvironment. Similar to solid tumors, ALL cells
819 can reach secondary sites and settle down, where they can remain dormant for years before
820 initiating a relapse. Although some intrinsic factors may predispose cells to invade one tissue
821 over another, the microenvironment undoubtedly plays an important role in leukemic cell
822 engraftment, making niche-based targeted therapies promising and worth developing.
823 However, given the complexity of the niches and the dynamic interconnections between each
824 microenvironmental actor, it will be a considerable challenge to elaborate therapies that can
825 efficiently and durably overcome resistance. Determining the appropriate placement of such
826 therapies in current treatment strategies is also an open question that will need to be
827 addressed.

828 **VIII. Practice points**

- 829 • ALL cells appear to localize preferentially in perivascular regions of the tissues they
830 colonize.

- Testicular, CNS and BM leukemic niches and solid tumor metastatic niches display similarities potentially accounting for the residence of leukemic cells in these preferred microenvironments.
- The interplay between leukemic niches and ALL cells is complex, dynamic and bidirectional.
- Relapses in specific tissues can be explained by both the microenvironment in these tissues and the intrinsic properties of ALL cells.
- Niche-based targeted therapies are currently being developed and may effectively prevent ALL relapses.
- Systemic treatments such as chemotherapy remain the best option to successfully treat extramedullary leukemia.

IX. Research agenda

- Further efforts are required to determine why leukemic cells settle preferentially in specific niches, to identify the most relevant microenvironmental features for therapeutic targeting.
- The combination of niche-based targeted treatments and conventional chemotherapy may prevent relapse.
- Clinicians should define the categories of patients most likely to benefit from such treatments.

REFERENCES

- [1] Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. *Cancer Causes Control* 2015;26:1627–42. doi:10.1007/s10552-015-0657-6.

855 [2] Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, et al.
856 Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic
857 Leukemia: A Children's Oncology Group Study. *J Clin Oncol* 2008;26:3971–8.
858 doi:10.1200/JCO.2008.16.1414.

859 [3] Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, et al. Long-Term
860 Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and
861 Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results
862 of Trial ALL-REZ BFM 90. *J Clin Oncol* 2010;28:2339–47. doi:10.1200/JCO.2009.25.1983.

863 [4] Gandemer V, Chevret S, Petit A, Vermylen C, Leblanc T, Michel G, et al. Excellent
864 prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia:
865 lessons from the FRALLE 93 protocol. *Haematologica* 2012;97:1743–50.
866 doi:10.3324/haematol.2011.059584.

867 [5] Oriol A, Vives S, Hernandez-Rivas JM, Tormo M, Heras I, Rivas C, et al. Outcome
868 after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive
869 risk-adapted trials by the PETHEMA Study Group. *Haematologica* 2010;95:589–96.
870 doi:10.3324/haematol.2009.014274.

871 [6] Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al.
872 Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC
873 UKALL12/ECOG 2993 study. *Blood* 2007;109:944–50. doi:10.1182/blood-2006-05-018192.

874 [7] Bhojwani D, Pui C-H. Relapsed childhood acute lymphoblastic leukaemia. *Lancet*
875 *Oncol* 2013;14:e205–17. doi:10.1016/S1470-2045(12)70580-6.

876 [8] Oskarsson T, Söderhäll S, Arvidson J, Forestier E, Montgomery S, Bottai M, et al.
877 Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors,
878 treatment and outcome. *Haematologica* 2016;101:68–76. doi:10.3324/haematol.2015.131680.

879 [9] Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. *N Engl J Med*
880 2015;373:1541–52. doi:10.1056/NEJMr1400972.

881 [10] Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, et al.
882 Monitoring minimal residual disease in children with high-risk relapses of acute
883 lymphoblastic leukemia: prognostic relevance of early and late assessment. *Leukemia*
884 2015;29:1648–55. doi:10.1038/leu.2015.59.

885 [11] Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel
886 R, et al. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in
887 relapsed childhood acute lymphoblastic leukemia allows for the identification of impending
888 relapse: results of the ALL-BFM-SCT 2003 trial. *J Clin Oncol Off J Am Soc Clin Oncol*
889 2015;33:1275–84. doi:10.1200/JCO.2014.58.4631.

890 [12] Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, et al. Minimal residual
891 disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute
892 lymphoblastic leukemia. *Leukemia* 2008;22:2193–200. doi:10.1038/leu.2008.227.

893 [13] Irving JAE. Towards an understanding of the biology and targeted treatment of
894 paediatric relapsed acute lymphoblastic leukaemia. *Br J Haematol* 2016;172:655–66.
895 doi:10.1111/bjh.13852.

896 [14] Jan M, Majeti R. Clonal evolution of acute leukemia genomes. *Oncogene*
897 2013;32:135–140.

898 [15] Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, et al. Genomic
899 Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia. *Science*
900 2008;322:1377–80. doi:10.1126/science.1164266.

901 [16] van Delft FW, Horsley S, Colman S, Anderson K, Bateman C, Kempinski H, et al.
902 Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. *Blood*
903 2011;117:6247–54. doi:10.1182/blood-2010-10-314674.

904 [17] Yang JJ, Bhojwani D, Yang W, Cai X, Stocco G, Crews K, et al. Genome-wide copy
905 number profiling reveals molecular evolution from diagnosis to relapse in childhood acute
906 lymphoblastic leukemia. *Blood* 2008;112:4178–83. doi:10.1182/blood-2008-06-165027.

907 [18] Ma X, Edmonson M, Yergeau D, Muzny DM, Hampton OA, Rusch M, et al. Rise and
908 fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. *Nat*
909 *Commun* 2015;6:6604. doi:10.1038/ncomms7604.

910 [19] Kuster L, Grausenburger R, Fuka G, Kaindl U, Krapf G, Inthal A, et al.
911 ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire
912 deletions of genes implicated in glucocorticoid signaling. *Blood* 2011;117:2658–67.
913 doi:10.1182/blood-2010-03-275347.

914 [20] Davidsson J, Paulsson K, Lindgren D, Lilljebjörn H, Chaplin T, Forestier E, et al.
915 Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic
916 ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations.
917 *Leukemia* 2010;24:924–31. doi:10.1038/leu.2010.39.

918 [21] Schmidt S, Irving JAE, Minto L, Matheson E, Nicholson L, Ploner A, et al.
919 Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the
920 level of the glucocorticoid receptor. *FASEB J* 2006;20:2600–2. doi:10.1096/fj.06-6214fje.

921 [22] Galen JC van, Kuiper RP, Emst L van, Levers M, Tijchon E, Scheijen B, et al. BTG1
922 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. *Blood*
923 2010;115:4810–9. doi:10.1182/blood-2009-05-223081.

924 [23] Bokemeyer A, Eckert C, Meyr F, Koerner G, Stackelberg A von, Ullmann R, et al.
925 Copy number genome alterations are associated with treatment response and outcome in
926 relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia. *Haematologica*
927 2014;99:706–14. doi:10.3324/haematol.2012.072470.

928 [24] Meyer JA, Wang J, Hogan LE, Yang JJ, Dandekar S, Patel JP, et al. Relapse-specific
929 mutations in NT5C2 in childhood acute lymphoblastic leukemia. *Nat Genet* 2013;45:290–4.
930 doi:10.1038/ng.2558.

931 [25] Li B, Li H, Bai Y, Kirschner-Schwabe R, Yang JJ, Chen Y, et al. Negative feedback-
932 defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. *Nat Med*
933 2015;21:563–71. doi:10.1038/nm.3840.

934 [26] Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, et al. Genetic
935 variegation of clonal architecture and propagating cells in leukaemia. *Nature* 2011;469:356–
936 61. doi:10.1038/nature09650.

937 [27] Dave DS, Leppert JT, Rajfer J. Is the Testis a Chemo-Privileged Site? Is There a
938 Blood-Testis Barrier? *Rev Urol* 2007;9:28–32.

939 [28] Pardridge WM. CSF, blood-brain barrier, and brain drug delivery. *Expert Opin Drug*
940 *Deliv* 2016;13:963–75. doi:10.1517/17425247.2016.1171315.

941 [29] Ford AM, Mansur MB, Furness CL, van Delft FW, Okamura J, Suzuki T, et al.
 942 Protracted dormancy of pre-leukemic stem cells. *Leukemia* 2015;29:2202–7.
 943 doi:10.1038/leu.2015.132.

944 [30] Spinella J-F, Richer C, Cassart P, Ouimet M, Healy J, Sinnett D. Mutational dynamics
 945 of early and late relapsed childhood ALL: rapid clonal expansion and long-term dormancy.
 946 *Blood Adv* 2018;2:177–88. doi:10.1182/bloodadvances.2017011510.

947 [31] Ruggiero A, Conter V, Milani M, Biagi E, Lazzareschi I, Sparano P, et al. Intrathecal
 948 Chemotherapy With Antineoplastic Agents in Children. *Paediatr Drugs* 2001;3:237–46.
 949 doi:10.2165/00128072-200103040-00001.

950 [32] Siu MKY, Cheng CY. THE BLOOD-FOLLICLE BARRIER (BFB) IN DISEASE
 951 AND IN OVARIAN FUNCTION. *Adv Exp Med Biol* 2012;763:186–92.

952 [33] Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM. Treatment of Acute
 953 Lymphoblastic Leukemia – 30 Years’ Experience at St. Jude Children’s Research Hospital. *N*
 954 *Engl J Med* 1993;329:1289–95. doi:10.1056/NEJM199310283291801.

955 [34] Sirvent N, Suciú S, Rialland X, Millot F, Benoit Y, Plantaz D, et al. Prognostic
 956 significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute
 957 lymphoblastic leukaemia (ALL) treated without cranial irradiation: Results of European
 958 Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group
 959 study 58881. *Eur J Cancer* 2011;47:239–47. doi:10.1016/j.ejca.2010.10.019.

960 [35] Brecher ML, Weinberg V, Boyett JM, Sinks LF, Jones B, Glicksman A, et al.
 961 Intermediate dose methotrexate in childhood acute lymphoblastic leukemia resulting in
 962 decreased incidence of testicular relapse. *Cancer* 1986;58:1024–8. doi:10.1002/1097-
 963 0142(19860901)58:5<1024::AID-CNCR2820580507>3.0.CO;2-V.

964 [36] Pui CH, Simone JV, Hancock ML, Evans WE, Williams DL, Bowman WP, et al.
 965 Impact of three methods of treatment intensification on acute lymphoblastic leukemia in
 966 children: long-term results of St Jude total therapy study X. *Leukemia* 1992;6:150–7.

967 [37] Ceppi F, Duval M, Leclerc J-M, Laverdiere C, Delva Y-L, Cellot S, et al. Improvement
 968 of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using
 969 a Risk-Based Treatment Strategy. *PLoS ONE* 2016;11. doi:10.1371/journal.pone.0160310.

970 [38] Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, et al. Intensive
 971 Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized
 972 Intercontinental Trial ALL IC-BFM 2002. *J Clin Oncol* 2014;32:174–84.
 973 doi:10.1200/JCO.2013.48.6522.

974 [39] Tsuchida M, Ohara A, Manabe A, Kumagai M, Shimada H, Kikuchi A, et al. Long-
 975 term results of Tokyo Children’s Cancer Study Group trials for childhood acute lymphoblastic
 976 leukemia, 1984–1999. *Leukemia* 2009;24:383–96. doi:10.1038/leu.2009.260.

977 [40] Reismüller B, Attarbaschi A, Peters C, Dworzak MN, Pötschger U, Urban C, et al.
 978 Long-term outcome of initially homogeneously treated and relapsed childhood acute
 979 lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-
 980 Frankfurt-Münster (BFM) Study Group. *Br J Haematol* 2009;144:559–70. doi:10.1111/j.1365-
 981 2141.2008.07499.x.

982 [41] Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, et al. Long-
 983 term results of five consecutive trials in childhood acute lymphoblastic leukemia performed

984 by the ALL-BFM study group from 1981 to 2000. *Leukemia* 2009;24:265–84.
985 doi:10.1038/leu.2009.257.

986 [42] Sipkins DA, Wei X, Wu JW, Runnels JM, Côté D, Means TK, et al. In vivo imaging of
987 specialized bone marrow endothelial microdomains for tumour engraftment. *Nature*
988 2005;435:969–73. doi:10.1038/nature03703.

989 [43] Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic
990 Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic
991 Progenitor Cells. *Science* 2008;322:1861–5. doi:10.1126/science.1164390.

992 [44] Duan C-W, Shi J, Chen J, Wang B, Yu Y-H, Qin X, et al. Leukemia Propagating Cells
993 Rebuild an Evolving Niche in Response to Therapy. *Cancer Cell* 2014;25:778–93.
994 doi:10.1016/j.ccr.2014.04.015.

995 [45] Ebinger S, Özdemir EZ, Ziegenhain C, Tiedt S, Castro Alves C, Grunert M, et al.
996 Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic
997 Leukemia. *Cancer Cell* 2016;30:849–62. doi:10.1016/j.ccell.2016.11.002.

998 [46] Roy A, Cargill A, Love S, Moorman AV, Stoneham S, Lim A, et al. Outcome after first
999 relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2
1000 trial. *Br J Haematol* 2005;130:67–75. doi:10.1111/j.1365-2141.2005.05572.x.

1001 [47] Hudson MM, Frankel LS, Mullins J, Swanson DA. Diagnostic value of surgical
1002 testicular biopsy after therapy for acute lymphocytic leukemia. *J Pediatr* 1985;107:50–3.

1003 [48] Tiedemann J, Chessells JM, Sandland RM. Isolated testicular relapse in boys with
1004 acute lymphoblastic leukaemia: treatment and outcome. *Br Med J Clin Res Ed*
1005 1982;285:1614–6.

1006 [49] Pui CH, Dahl GV, Bowman WP, Rao BN, Abromowitch M, Ochs J, et al. Elective
1007 testicular biopsy during chemotherapy for childhood leukaemia is of no clinical value. *Lancet*
1008 *Lond Engl* 1985;2:410–2.

1009 [50] Ortega JJ, Javier G, Torán N. Testicular infiltrates in children with acute lymphoblastic
1010 leukemia: a prospective study. *Pediatr Blood Cancer* 1984;12:386–393.

1011 [51] Wong KY, Ballard ET, Strayer FH, Kisker CT, Lampkin BC. Clinical and occult
1012 testicular leukemia in long-term survivors of acute lymphoblastic leukemia. *J Pediatr*
1013 1980;96:569–574.

1014 [52] Prince FP, Palmer NF, Newton WA. Ultrastructural criteria in evaluating leukemic
1015 infiltration in prepubertal testicular biopsies. *Pediatr Pathol* 1986;5:17–29.

1016 [53] Jahnukainen K, Hou M, Petersen C, Setchell B, Söder O. Intratesticular
1017 Transplantation of Testicular Cells from Leukemic Rats Causes Transmission of Leukemia.
1018 *Cancer Res* 2001;61:706–10.

1019 [54] Jahnukainen K, Morris I, Roe S, Salmi TT, Mäkipernaa A, Pöllänen P. A rodent model
1020 for testicular involvement in acute lymphoblastic leukaemia. *Br J Cancer* 1993;67:885.

1021 [55] Jackson H, Jackson NC, Bock M, Lendon M. Testicular invasion and relapse and
1022 meningeal involvement in a rat T-cell leukaemia. *Br J Cancer* 1984;50:617–24.

1023 [56] Jackson H, Jackson NC, Bock M, Lendon M. Testicular relapse in acute lymphoblastic
1024 leukaemia: studies with an experimental mouse model. *Br J Cancer* 1984;49:73–8.

1025 [57] Reid H, Marsden HB. Gonadal infiltration in children with leukaemia and lymphoma.
1026 J Clin Pathol 1980;33:722–9.

1027 [58] Cunningham I. The clinical behavior of 124 leukemic ovarian tumors: clues for
1028 improving the poor prognosis. Leuk Lymphoma 2013;54:1430–6.
1029 doi:10.3109/10428194.2012.745522.

1030 [59] Hagedorn N, Acquaviva C, Fronkova E, Stackelberg A von, Barth A, Stadt U zur, et al.
1031 Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood
1032 acute lymphoblastic leukemia: a more precise definition of “isolated” and its possible clinical
1033 implications, a collaborative study of the Resistant Disease Committee of the International
1034 BFM study group. Blood 2007;110:4022–9. doi:10.1182/blood-2007-04-082040.

1035 [60] Himelstein-Braw R, Peters H, Faber M. Morphological study of the ovaries of
1036 leukaemic children. Br J Cancer 1978;38:82–7.

1037 [61] Viadana E, Bross ID, Pickren JW. An autopsy study of the metastatic patterns of
1038 human leukemias. Oncology 1978;35:87–96.

1039 [62] Kyono K, Doshida M, Toya M, Sato Y, Akahira J, Sasano H. Potential indications for
1040 ovarian autotransplantation based on the analysis of 5,571 autopsy findings of females under
1041 the age of 40 in Japan. Fertil Steril 2010;93:2429–30. doi:10.1016/j.fertnstert.2009.08.031.

1042 [63] Nunes V, Della Starza I, Canichella M, Cavalli M, De Propriis MS, Messina M, et al. A
1043 case of late isolated ovarian relapse of acute lymphoblastic leukemia after an allogeneic stem
1044 cell transplant. Leuk Lymphoma 2015;56:1517–20. doi:10.3109/10428194.2014.956317.

1045 [64] Dolmans M-M, Marinescu C, Saussoy P, Langendonck AV, Amorim C, Donnez J.
1046 Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic
1047 leukemia is potentially unsafe. Blood 2010;116:2908–14. doi:10.1182/blood-2010-01-265751.

1048 [65] Rosendahl M, Andersen MT, Ralfkiær E, Kjeldsen L, Andersen MK, Andersen CY.
1049 Evidence of residual disease in cryopreserved ovarian cortex from female patients with
1050 leukemia. Fertil Steril 2010;94:2186–90. doi:10.1016/j.fertnstert.2009.11.032.

1051 [66] Jahnukainen K, Tinkanen H, Wikström A, Dunkel L, Saarinen-Pihkala UM, Mäkinen
1052 S, et al. Bone marrow remission status predicts leukemia contamination in ovarian biopsies
1053 collected for fertility preservation. Leukemia 2013;27:1183–5. doi:10.1038/leu.2012.279.

1054 [67] Soares M, Saussoy P, Maskens M, Reul H, Amorim CA, Donnez J, et al. Eliminating
1055 malignant cells from cryopreserved ovarian tissue is possible in leukaemia patients. Br J
1056 Haematol 2017;178:231–9. doi:10.1111/bjh.14657.

1057 [68] Price RA, Johnson WW. The central nervous system in childhood leukemia: I. The
1058 arachnoid. Cancer 1973;31:520–33. doi:10.1002/1097-0142(197303)31:3<520::AID-
1059 CNCR2820310306>3.0.CO;2-2.

1060 [69] Williams MTS, Yousafzai YM, Elder A, Rehe K, Bomken S, Frishman-Levy L, et al.
1061 The ability to cross the blood–cerebrospinal fluid barrier is a generic property of acute
1062 lymphoblastic leukemia blasts. Blood 2016;127:1998–2006. doi:10.1182/blood-2015-08-
1063 665034.

1064 [70] Barone TA, Plunkett RJ, Hohmann P, Lis A, Glenister N, Barcos M, et al. An
1065 Experimental Model of Human Leukemic Meningitis in the Nude Rat. Blood 1997;90:298–
1066 305.

1067 [71] Ginsberg LE, Leeds NE. Neuroradiology of leukemia. *AJR Am J Roentgenol*
1068 1995;165:525–34. doi:10.2214/ajr.165.3.7645463.

1069 [72] Ulu EMK, Töre HG, Bayrak A, Güngör D, Coskun M. MRI of central nervous system
1070 abnormalities in childhood leukemia. *Diagn Interv Radiol* 2009;15:86.

1071 [73] Isome K, Matsubara K, Taki T, Nigami H, Yura K, Iwata A, et al. Spinal Cord
1072 Compression by Epidural Involvement Over 21 Vertebral Levels in Acute Lymphoblastic
1073 Leukemia: *J Pediatr Hematol Oncol* 2011;33:153–7. doi:10.1097/MPH.0b013e3181e005b2.

1074 [74] Yao H, Price TT, Cantelli G, Ngo B, Warner MJ, Olivere L, et al. Leukaemia hijacks a
1075 neural mechanism to invade the central nervous system. *Nature* 2018;560:55–60.
1076 doi:10.1038/s41586-018-0342-5.

1077 [75] Cunningham I. Extramedullary sites of leukemia relapse after transplant. *Leuk*
1078 *Lymphoma* 2006;47:1754–67. doi:10.1080/10428190600632857.

1079 [76] Cunningham I. A clinical review of breast involvement in acute leukemia. *Leuk*
1080 *Lymphoma* 2006;47:2517–26. doi:10.1080/10428190600967022.

1081 [77] Cunningham I. A basis for updating our approach to resistant acute leukemia. *Am J*
1082 *Hematol* 2012;87:251–7. doi:10.1002/ajh.22256.

1083 [78] Cunningham I, Kohno B. 18FDG-PET/CT: 21st century approach to leukemic tumors
1084 in 124 cases. *Am J Hematol* 2016;91:379–84. doi:10.1002/ajh.24287.

1085 [79] Karbasian-Esfahani M, Wiernik PH, Yeddu M, Abebe L. Leukemic infiltration of the
1086 breast in acute lymphocytic leukemia (ALL). *Hematol Amst Neth* 2008;13:101–6.
1087 doi:10.1179/102453308X315933.

1088 [80] Sison EAR, Brown P. The bone marrow microenvironment and leukemia: biology and
1089 therapeutic targeting. *Expert Rev Hematol* 2011;4:271–83. doi:10.1586/ehm.11.30.

1090 [81] Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells.
1091 *Nature* 2014;505:327–34. doi:10.1038/nature12984.

1092 [82] Calvi LM, Link DC. The hematopoietic stem cell niche in homeostasis and disease.
1093 *Blood* 2015;126:2443–51. doi:10.1182/blood-2015-07-533588.

1094 [83] Chiarini F, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C, et al.
1095 Advances in understanding the acute lymphoblastic leukemia bone marrow
1096 microenvironment: From biology to therapeutic targeting. *Biochim Biophys Acta BBA - Mol*
1097 *Cell Res* 2016;1863:449–63. doi:10.1016/j.bbamcr.2015.08.015.

1098 [84] Crane GM, Jeffery E, Morrison SJ. Adult haematopoietic stem cell niches. *Nat Rev*
1099 *Immunol* 2017;17:573–90. doi:10.1038/nri.2017.53.

1100 [85] Schofield R. The relationship between the spleen colony-forming cell and the
1101 haemopoietic stem cell. *Blood Cells* 1978;4:7–25.

1102 [86] Calvi LM, Link DC. The hematopoietic stem cell niche in homeostasis and disease.
1103 *Blood* 2015;126:2443–51. doi:10.1182/blood-2015-07-533588.

1104 [87] Tabe Y, Konopleva M. Advances in understanding the leukaemia microenvironment.
1105 *Br J Haematol* 2014;164:767–78. doi:10.1111/bjh.12725.

1106 [88] Hira VVV, Van Noorden CJF, Carraway HE, Maciejewski JP, Molenaar RJ. Novel
1107 therapeutic strategies to target leukemic cells that hijack compartmentalized continuous

1108 hematopoietic stem cell niches. *Biochim Biophys Acta BBA - Rev Cancer* 2017;1868:183–98.
1109 doi:10.1016/j.bbcan.2017.03.010.

1110 [89] Kazanis I, Lathia J, Moss L, French-Constant C. The neural stem cell
1111 microenvironment. *StemBook*, Cambridge (MA): Harvard Stem Cell Institute; 2008.

1112 [90] Basak O, Taylor V. Stem cells of the adult mammalian brain and their niche. *Cell Mol*
1113 *Life Sci* 2009;66:1057–72. doi:10.1007/s00018-008-8544-x.

1114 [91] Lin R, Iacovitti L. Classic and novel stem cell niches in brain homeostasis and repair.
1115 *Brain Res* 2015;1628:327–42. doi:10.1016/j.brainres.2015.04.029.

1116 [92] Oatley JM, Brinster RL. THE GERMLINE STEM CELL NICHE UNIT IN
1117 MAMMALIAN TESTES. *Physiol Rev* 2012;92:577–95. doi:10.1152/physrev.00025.2011.

1118 [93] Mruk DD, Cheng CY. The Mammalian Blood-Testis Barrier: Its Biology and
1119 Regulation. *Endocr Rev* 2015;36:564–91. doi:10.1210/er.2014-1101.

1120 [94] Descot A, Oskarsson T. The molecular composition of the metastatic niche. *Exp Cell*
1121 *Res* 2013;319:1679–86. doi:10.1016/j.yexcr.2013.04.017.

1122 [95] Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. *Cell*
1123 2011;144:646–74. doi:10.1016/j.cell.2011.02.013.

1124 [96] Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W. CXCL12/CXCR4: a symbiotic
1125 bridge linking cancer cells and their stromal neighbors in oncogenic communication
1126 networks. *Oncogene* 2015.

1127 [97] Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the Hematopoietic
1128 Stem Cell Pool by CXCL12-CXCR4 Chemokine Signaling in Bone Marrow Stromal Cell
1129 Niches. *Immunity* 2006;25:977–88. doi:10.1016/j.immuni.2006.10.016.

1130 [98] Dar A, Goichberg P, Shinder V, Kalinkovich A, Kollet O, Netzer N, et al. Chemokine
1131 receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by
1132 bone marrow endothelial and stromal cells. *Nat Immunol* 2005;6:1038–46.
1133 doi:10.1038/ni1251.

1134 [99] Scala S. Molecular Pathways: Targeting the CXCR4–CXCL12 Axis—Untapped
1135 Potential in the Tumor Microenvironment. *Clin Cancer Res* 2015;21:4278–85.
1136 doi:10.1158/1078-0432.CCR-14-0914.

1137 [100] Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, et al. CXCL12/CXCR4/CXCR7
1138 Chemokine Axis and Cancer Progression. *Cancer Metastasis Rev* 2010;29:709–22.
1139 doi:10.1007/s10555-010-9256-x.

1140 [101] Barbolina MV, Kim M, Liu Y, Shepard J, Belmadani A, Miller RJ, et al.
1141 Microenvironmental Regulation of Chemokine (C-X-C-motif) Receptor 4 in Ovarian
1142 Carcinoma. *Mol Cancer Res MCR* 2010;8:653–64. doi:10.1158/1541-7786.MCR-09-0463.

1143 [102] Kasagi Y, Harada Y, Morodomi Y, Iwai T, Saito S, Yoshida K, et al. Peritoneal
1144 Dissemination Requires an Sp1-Dependent CXCR4/CXCL12 Signaling Axis and
1145 Extracellular Matrix-Directed Spheroid Formation. *Cancer Res* 2016;76:347–57.
1146 doi:10.1158/0008-5472.CAN-15-1563.

1147 [103] Ogawa F, Amano H, Eshima K, Ito Y, Matsui Y, Hosono K, et al. Prostanoid induces
1148 premetastatic niche in regional lymph nodes. *J Clin Invest* 2014;124:4882–94.
1149 doi:10.1172/JCI73530.

1150 [104] Nishii K, Katayama N, Miwa H, Shikami M, Masuya M, Shiku H, et al. Survival of
 1151 human leukaemic B-cell precursors is supported by stromal cells and cytokines: association
 1152 with the expression of bcl-2 protein. *Br J Haematol* 1999;105:701–10.

1153 [105] Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ. Effects of inhibitors of the
 1154 chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. *Leukemia*
 1155 2003;17:1294–300. doi:10.1038/sj.leu.2402998.

1156 [106] Gilbert DC, Chandler I, McIntyre A, Goddard NC, Gabe R, Huddart RA, et al. Clinical
 1157 and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell
 1158 tumours of adults and adolescents. *J Pathol* 2009;217:94–102. doi:10.1002/path.2436.

1159 [107] McIver SC, Loveland KL, Roman SD, Nixon B, Kitazawa R, McLaughlin EA. The
 1160 chemokine CXCL12 and its receptor CXCR4 are implicated in human seminoma metastasis.
 1161 *Andrology* 2013;1:517–29. doi:10.1111/j.2047-2927.2013.00081.x.

1162 [108] Westernströer B, Langenstroth D, Kliesch S, Troppmann B, Redmann K, Macdonald J,
 1163 et al. Developmental expression patterns of chemokines CXCL11, CXCL12 and their receptor
 1164 CXCR7 in testes of common marmoset and human. *Cell Tissue Res* 2015;361:885–98.
 1165 doi:10.1007/s00441-015-2164-1.

1166 [109] Tröndle I, Westernströer B, Wistuba J, Terwort N, Schlatt S, Neuhaus N. Irradiation
 1167 affects germ and somatic cells in prepubertal monkey testis xenografts. *Mol Hum Reprod*
 1168 2017;23:141–54. doi:10.1093/molehr/gax003.

1169 [110] Arnaud M-P, Vallée A, Robert G, Bonneau J, Leroy C, Varin-Blank N, et al. CD9, a
 1170 key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated
 1171 migration via RAC1 signaling. *Blood* 2015;126:1802–12. doi:10.1182/blood-2015-02-
 1172 628560.

1173 [111] Kobayashi H, Urashima M, Hoshi Y, Uchiyama H, Fujisawa K, Akatsuka J, et al.
 1174 Testicular morphological changes in children with acute lymphoblastic leukemia following
 1175 chemotherapy. *Acta Paediatr Jpn Overseas Ed* 1996;38:640–3.

1176 [112] Guyon A. CXCL12 chemokine and its receptors as major players in the interactions
 1177 between immune and nervous systems. *Front Cell Neurosci* 2014;8.
 1178 doi:10.3389/fncel.2014.00065.

1179 [113] Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T, et al. Impaired
 1180 B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and
 1181 SDF-1-deficient mice. *Proc Natl Acad Sci U S A* 1998;95:9448–53.

1182 [114] Lu M, Grove EA, Miller RJ. Abnormal development of the hippocampal dentate gyrus
 1183 in mice lacking the CXCR4 chemokine receptor. *Proc Natl Acad Sci U S A* 2002;99:7090–5.
 1184 doi:10.1073/pnas.092013799.

1185 [115] Lazarini F, Tham TN, Casanova P, Arenzana-Seisdedos F, Dubois-Dalcq M. Role of
 1186 the α -chemokine stromal cell-derived factor (SDF-1) in the developing and mature central
 1187 nervous system. *Glia* 2003;42:139–48. doi:10.1002/glia.10139.

1188 [116] Yang S, Edman LC, Sánchez-Alcañiz JA, Fritz N, Bonilla S, Hecht J, et al.
 1189 Cxcl12/Cxcr4 signaling controls the migration and process orientation of A9-A10
 1190 dopaminergic neurons. *Development* 2013;140:4554–64. doi:10.1242/dev.098145.

1191 [117] Stumm RK, Rummel J, Junker V, Culmsee C, Pfeiffer M, Kriegelstein J, et al. A Dual
 1192 Role for the SDF-1/CXCR4 Chemokine Receptor System in Adult Brain: Isoform-Selective

1193 Regulation of SDF-1 Expression Modulates CXCR4-Dependent Neuronal Plasticity and
1194 Cerebral Leukocyte Recruitment after Focal Ischemia. *J Neurosci* 2002;22:5865–78.

1195 [118] Bajetto A, Bonavia R, Barbero S, Piccioli P, Costa A, Florio T, et al. Glial and
1196 Neuronal Cells Express Functional Chemokine Receptor CXCR4 and Its Natural Ligand
1197 Stromal Cell-Derived Factor 1. *J Neurochem* 1999;73:2348–57. doi:10.1046/j.1471-
1198 4159.1999.0732348.x.

1199 [119] McCandless EE, Wang Q, Woerner BM, Harper JM, Klein RS. CXCL12 Limits
1200 Inflammation by Localizing Mononuclear Infiltrates to the Perivascular Space during
1201 Experimental Autoimmune Encephalomyelitis. *J Immunol* 2006;177:8053–64.
1202 doi:10.4049/jimmunol.177.11.8053.

1203 [120] McCandless EE, Piccio L, Woerner BM, Schmidt RE, Rubin JB, Cross AH, et al.
1204 Pathological Expression of CXCL12 at the Blood-Brain Barrier Correlates with Severity of
1205 Multiple Sclerosis. *Am J Pathol* 2008;172:799–808. doi:10.2353/ajpath.2008.070918.

1206 [121] Jost Tanja Rezzonico, Borga Chiara, Radaelli Enrico, Romagnani Andrea, Perruzza
1207 Lisa, Omodho Lorna, et al. Role of CXCR4-mediated bone marrow colonization in CNS
1208 infiltration by T cell acute lymphoblastic leukemia. *J Leukoc Biol* 2016;99:1077–87.
1209 doi:10.1189/jlb.5MA0915-394R.

1210 [122] Alsadeq A, Fedders H, Vokuhl C, Belau NM, Zimmermann M, Wirbelauer T, et al.
1211 The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous
1212 system. *Haematologica* 2017;102:346–55. doi:10.3324/haematol.2016.147744.

1213 [123] Crazzolara R, Kreczy A, Mann G, Heitger A, Eibl G, Fink FM, et al. High expression
1214 of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood
1215 acute lymphoblastic leukaemia. *Br J Haematol* 2001;115:545–53.

1216 [124] Juarez J, Pena AD, Baraz R, Hewson J, Khoo M, Cisterne A, et al. CXCR4 antagonists
1217 mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit
1218 engraftment. *Leukemia* 2007;21:1249–57. doi:10.1038/sj.leu.2404684.

1219 [125] Kato I, Niwa A, Heike T, Fujino H, Saito MK, Umeda K, et al. Identification of
1220 Hepatic Niche Harboring Human Acute Lymphoblastic Leukemic Cells via the SDF-
1221 1/CXCR4 Axis. *PLOS ONE* 2011;6:e27042. doi:10.1371/journal.pone.0027042.

1222 [126] Ivanovic Z. Hypoxia or in situ normoxia: The stem cell paradigm. *J Cell Physiol*
1223 2009;219:271–5. doi:10.1002/jcp.21690.

1224 [127] Eliasson P, Jönsson J-I. The hematopoietic stem cell niche: Low in oxygen but a nice
1225 place to be. *J Cell Physiol* 2010;222:17–22. doi:10.1002/jcp.21908.

1226 [128] Ishikawa Y, Ito T. Kinetics of hemopoietic stem cells in a hypoxic culture. *Eur J*
1227 *Haematol* 1988;40:126–9.

1228 [129] Chow DC, Wenning LA, Miller WM, Papoutsakis ET. Modeling pO(2) distributions in
1229 the bone marrow hematopoietic compartment. I. Krogh's model. *Biophys J* 2001;81:675–84.
1230 doi:10.1016/S0006-3495(01)75732-3.

1231 [130] Chow DC, Wenning LA, Miller WM, Papoutsakis ET. Modeling pO(2) distributions in
1232 the bone marrow hematopoietic compartment. II. Modified Kroghian models. *Biophys J*
1233 2001;81:685–96. doi:10.1016/S0006-3495(01)75733-5.

1234 [131] Spencer JA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM, et al. Direct
1235 measurement of local oxygen concentration in the bone marrow of live animals. *Nature*
1236 2014;508:269–73. doi:10.1038/nature13034.

1237 [132] Parmar K, Mauch P, Vergilio J-A, Sackstein R, Down JD. Distribution of
1238 hematopoietic stem cells in the bone marrow according to regional hypoxia. *Proc Natl Acad*
1239 *Sci* 2007;104:5431–6. doi:10.1073/pnas.0701152104.

1240 [133] Ivanovic Z, Hermitte F, Brunet de la Grange P, Dazey B, Belloc F, Lacombe F, et al.
1241 Simultaneous maintenance of human cord blood SCID-repopulating cells and expansion of
1242 committed progenitors at low O₂ concentration (3%). *Stem Cells Dayt Ohio* 2004;22:716–24.
1243 doi:10.1634/stemcells.22-5-716.

1244 [134] Guitart AV, Hammoud M, Dello Sbarba P, Ivanovic Z, Praloran V. Slow-
1245 cycling/quiescence balance of hematopoietic stem cells is related to physiological gradient of
1246 oxygen. *Exp Hematol* 2010;38:847–51. doi:10.1016/j.exphem.2010.06.002.

1247 [135] Kovačević-Filipović M, Petakov M, Hermitte F, Debeissat C, Krstić A, Jovčić G, et al.
1248 Interleukin-6 (IL-6) and low O₂ concentration (1%) synergize to improve the maintenance of
1249 hematopoietic stem cells (pre-CFC). *J Cell Physiol* 2007;212:68–75. doi:10.1002/jcp.21003.

1250 [136] Hermitte F, Brunet de la Grange P, Belloc F, Praloran V, Ivanovic Z. Very low O₂
1251 concentration (0.1%) favors G₀ return of dividing CD34⁺ cells. *Stem Cells Dayt Ohio*
1252 2006;24:65–73. doi:10.1634/stemcells.2004-0351.

1253 [137] Nombela-Arrieta C, Pivarnik G, Winkel B, Canty KJ, Harley B, Mahoney JE, et al.
1254 Quantitative Imaging of Hematopoietic Stem and Progenitor Cell localization and hypoxic
1255 status in the Bone Marrow microenvironment. *Nat Cell Biol* 2013;15:533–43.
1256 doi:10.1038/ncb2730.

1257 [138] Philip B, Ito K, Moreno-Sánchez R, Ralph SJ. HIF expression and the role of hypoxic
1258 microenvironments within primary tumours as protective sites driving cancer stem cell
1259 renewal and metastatic progression. *Carcinogenesis* 2013;34:1699–707.
1260 doi:10.1093/carcin/bgt209.

1261 [139] Chen A, Sceneay J, Gödde N, Kinwel T, Ham S, Thompson EW, et al. Intermittent
1262 hypoxia induces a metastatic phenotype in breast cancer. *Oncogene* 2018.
1263 doi:10.1038/s41388-018-0259-3.

1264 [140] Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan P-F, Shimamura T, et al. HIF1 α
1265 and HIF2 α independently activate SRC to promote melanoma metastases. *J Clin Invest*
1266 2013;123:2078–93. doi:10.1172/JCI66715.

1267 [141] Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, et al. Pronounced hypoxia in
1268 models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.
1269 *PloS One* 2011;6:e23108. doi:10.1371/journal.pone.0023108.

1270 [142] Dong-Feng Z, Ting L, Cheng C, Xi Z, Xue L, Xing-Hua C, et al. Silencing HIF-1 α
1271 reduces the adhesion and secretion functions of acute leukemia hBMSCs. *Braz J Med Biol*
1272 *Res* 2012;45:906–12. doi:10.1590/S0100-879X2012007500107.

1273 [143] Jamieson SMF, Gu Y, Manesh DM, El-Hoss J, Jing D, Mackenzie KL, et al. A novel
1274 fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen
1275 mustard prodrug PR-104A in human leukaemia cells. *Biochem Pharmacol* 2014;88:36–45.
1276 doi:10.1016/j.bcp.2013.12.019.

1277 [144] Benito J, Zeng Z, Konopleva M, Wilson WR. Targeting hypoxia in the leukemia
1278 microenvironment. *Int J Hematol Oncol* 2013;2:279–288.

1279 [145] Konopleva M, Thall PF, Yi CA, Borthakur G, Covelev A, Bueso-Ramos C, et al. Phase
1280 I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid
1281 leukemia and acute lymphoblastic leukemia. *Haematologica* 2015;100:927–34.
1282 doi:10.3324/haematol.2014.118455.

1283 [146] Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, et al. A
1284 Phase I Study of Evofosfamide, an Investigational Hypoxia-Activated Prodrug, in Patients
1285 with Advanced Leukemia. *Am J Hematol* 2016;91:800–5. doi:10.1002/ajh.24415.

1286 [147] Benito J, Ramirez MS, Millward NZ, Velez J, Harutyunyan KG, Lu H, et al. Hypoxia-
1287 Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia
1288 Models. *Clin Cancer Res* 2016;22:1687–98. doi:10.1158/1078-0432.CCR-14-3378.

1289 [148] Schito L, Rey S, Konopleva M. Integration of hypoxic HIF- α signaling in blood
1290 cancers. *Oncogene* 2017;36:5331–40. doi:10.1038/onc.2017.119.

1291 [149] Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, et al.
1292 Regulation of HIF-1 α signaling and chemoresistance in acute lymphocytic leukemia under
1293 hypoxic conditions of the bone marrow microenvironment. *Cancer Biol Ther* 2012;13:858–
1294 870.

1295 [150] Petit C, Gouel F, Dubus I, Heuclin C, Roget K, Vannier JP. Hypoxia promotes
1296 chemoresistance in acute lymphoblastic leukemia cell lines by modulating death signaling
1297 pathways. *BMC Cancer* 2016;16:746. doi:10.1186/s12885-016-2776-1.

1298 [151] Free MJ, Schluntz, Jaffe. *Respiratory Gas Tensions in Tissues and Fluids of the Male*
1299 *Rat Reproductive Tract* 1976.

1300 [152] Klotz T, Vorreuther R, Heidenreich A, Zumbé J, Engelmann U. Testicular tissue
1301 oxygen pressure. *J Urol* 1996;155:1488–91.

1302 [153] Gruber G, Carlet M, Türtscher E, Meister B, Irving J a. E, Ploner C, et al. Levels of
1303 glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-
1304 induced leukemia apoptosis. *Leukemia* 2009;23:820–3. doi:10.1038/leu.2008.360.

1305 [154] Yarnell P, Charlton G, Merrill CR, Ghiardi F, Ommaya AK. Dynamics of oxygen
1306 tension in the cisternal cerebrospinal fluid of the rhesus monkey. *J Neurosurg* 1967;27:515–
1307 24. doi:10.3171/jns.1967.27.6.0515.

1308 [155] Kishikawa H, Iwatsuki K, Fujimoto S, Umeda A. Body fluid oxygen tension and
1309 prognosis in patients with ruptured aneurysm. *Stroke* 1979;10:560–3.

1310 [156] Sharan M, Vovenko EP, Vadapalli A, Popel AS, Pittman RN. Experimental and
1311 theoretical studies of oxygen gradients in rat pial microvessels. *J Cereb Blood Flow Metab*
1312 *Off J Int Soc Cereb Blood Flow Metab* 2008;28:1597–604. doi:10.1038/jcbfm.2008.51.

1313 [157] Kato I, Nishinaka Y, Nakamura M, Akarca AU, Niwa A, Ozawa H, et al. Hypoxic
1314 adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting
1315 VEGFA. *Blood* 2017;129:3126–9. doi:10.1182/blood-2016-06-721712.

1316 [158] Münch V, Trentin L, Herzig J, Demir S, Seyfried F, Kraus JM, et al. Central nervous
1317 system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial
1318 growth factor. *Blood* 2017;130:643–54. doi:10.1182/blood-2017-03-769315.

1319 [159] Tang Y-T, Jiang F, Guo L, Si M-Y, Jiao X-Y. Expression and significance of vascular
1320 endothelial growth factor A and C in leukemia central nervous system metastasis. *Leuk Res*
1321 2013;37:359–66. doi:10.1016/j.leukres.2012.10.008.

1322 [160] Izraeli S, Eckert C. Targeted therapy of CNS leukemia? *Blood* 2017;130:562–3.
1323 doi:10.1182/blood-2017-06-788430.

1324 [161] Lyman SD, Jacobsen SEW. c-kit Ligand and Flt3 Ligand: Stem/Progenitor Cell
1325 Factors With Overlapping Yet Distinct Activities. *Blood* 1998;91:1101–34.

1326 [162] Ashman LK. The biology of stem cell factor and its receptor C-kit. *Int J Biochem Cell*
1327 *Biol* 1999;31:1037–51.

1328 [163] Lennartsson J, Rönstrand L. Stem Cell Factor Receptor/c-Kit: From Basic Science to
1329 Clinical Implications. *Physiol Rev* 2012;92:1619–49. doi:10.1152/physrev.00046.2011.

1330 [164] Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells
1331 maintain haematopoietic stem cells. *Nature* 2012;481:457–62. doi:10.1038/nature10783.

1332 [165] Huang EJ, Nocka KH, Buck J, Besmer P. Differential expression and processing of
1333 two cell associated forms of the kit-ligand: KL-1 and KL-2. *Mol Biol Cell* 1992;3:349–62.

1334 [166] Flanagan JG, Chan DC, Leder P. Transmembrane form of the kit ligand growth factor
1335 is determined by alternative splicing and is missing in the Sld mutant. *Cell* 1991;64:1025–35.
1336 doi:10.1016/0092-8674(91)90326-T.

1337 [167] Kinashi T, Springer TA. Steel factor and c-kit regulate cell-matrix adhesion. *Blood*
1338 1994;83:1033–8.

1339 [168] Driessen RL, Johnston HM, Nilsson SK. Membrane-bound stem cell factor is a key
1340 regulator in the initial lodgment of stem cells within the endosteal marrow region. *Exp*
1341 *Hematol* 2003;31:1284–91. doi:10.1016/j.exphem.2003.08.015.

1342 [169] Okumura N, Tsuji K, Ebihara Y, Tanaka I, Sawai N, Koike K, et al. Chemotactic and
1343 chemokinetic activities of stem cell factor on murine hematopoietic progenitor cells. *Blood*
1344 1996;87:4100–8.

1345 [170] Huang B, Lei Z, Zhang G-M, Li D, Song C, Li B, et al. SCF-mediated mast cell
1346 infiltration and activation exacerbate the inflammation and immunosuppression in tumor
1347 microenvironment. *Blood* 2008;112:1269–79. doi:10.1182/blood-2008-03-147033.

1348 [171] Figueira MI, Cardoso HJ, Correia S, Maia CJ, Socorro S. The stem cell factor
1349 (SCF)/c-KIT system in carcinogenesis of reproductive tissues: What does the hormonal
1350 regulation tell us? *Cancer Lett* 2017;405:10–21. doi:10.1016/j.canlet.2017.07.017.

1351 [172] Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic
1352 tissues, and mutations and their clinicopathologic correlation. *Appl Immunohistochem Mol*
1353 *Morphol AIMM* 2005;13:205–20.

1354 [173] Zhou X, Edmonson MN, Wilkinson MR, Patel A, Wu G, Liu Y, et al. Exploring
1355 genomic alteration in pediatric cancer using ProteinPaint. *Nat Genet* 2016;48:4–6.
1356 doi:10.1038/ng.3466.

1357 [174] Debaize L, Jakobczyk H, Avner S, Gaudichon J, Rio A-G, Sérandour AA, et al.
1358 Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the
1359 oncogene c-KIT and amplifies cell proliferation. *Nucleic Acids Res* 2018;30;46(21):11214-
1360 11228. doi:10.1093/nar/gky756.

1361 [175] Muciaccia B, Sette C, Paronetto MP, Barchi M, Pensini S, D'Agostino A, et al.
 1362 Expression of a truncated form of KIT tyrosine kinase in human spermatozoa correlates with
 1363 sperm DNA integrity. *Hum Reprod* 2010;25:2188–202. doi:10.1093/humrep/deq168.

1364 [176] Unni SK, Modi DN, Pathak SG, Dhabalia JV, Bhartiya D. Stage-specific Localization
 1365 and Expression of c-kit in the Adult Human Testis. *J Histochem Cytochem* 2009;57:861–9.
 1366 doi:10.1369/jhc.2009.953737.

1367 [177] Fox RA, Sigman M, Boekelheide K. Transmembrane versus soluble stem cell factor
 1368 expression in human testis. *J Androl* 2000;21:579–85.

1369 [178] Motro B, van der Kooy D, Rossant J, Reith A, Bernstein A. Contiguous patterns of c-
 1370 kit and steel expression: analysis of mutations at the W and Sl loci. *Dev Camb Engl*
 1371 1991;113:1207–21.

1372 [179] Sandlow JI, Feng H-L, Sandra A. Localization and expression of the c-Kit receptor
 1373 protein in human and rodent testis and sperm. *Urology* 1997;49:494–500. doi:10.1016/S0090-
 1374 4295(96)00494-3.

1375 [180] Stoop H, Honecker F, van de Geijn GJM, Gillis AJM, Cools MC, de Boer M, et al.
 1376 Stem cell factor as a novel diagnostic marker for early malignant germ cells. *J Pathol*
 1377 2008;216:43–54. doi:10.1002/path.2378.

1378 [181] Strohmeyer T, Reese D, Press M, Ackermann R, Hartmann M, Slamon D. Expression
 1379 of the c-kit Proto-Oncogene and Its Ligand Stem Cell Factor (SCF) in Normal and Malignant
 1380 Human Testicular Tissue. *J Urol* 1995;153:511–5. doi:10.1097/00005392-199502000-00073.

1381 [182] Guijarro P, Wang Y, Ying Y, Yao Y, Jieyi X, Yuan X. In vivo knockdown of ckit
 1382 impairs neuronal migration and axonal extension in the cerebral cortex. *Dev Neurobiol*
 1383 2013;73:871–87. doi:10.1002/dneu.22107.

1384 [183] Kallmann B-A, Wagner S, Hummel V, Buttmann M, Bayas A, Tonn JC, et al.
 1385 Characteristic gene expression profile of primary human cerebral endothelial cells. *FASEB J*
 1386 2002;16:589–91. doi:10.1096/fj.01-0594fje.

1387 [184] Schutzer SE, Liu T, Natelson BH, Angel TE, Schepmoes AA, Purvine SO, et al.
 1388 Establishing the Proteome of Normal Human Cerebrospinal Fluid. *PLOS ONE*
 1389 2010;5:e10980. doi:10.1371/journal.pone.0010980.

1390 [185] Bastos ACSF, Blunck CB, Emerenciano M, Gimba ERP. Osteopontin and their roles in
 1391 hematological malignancies: Splice variants on the new avenues. *Cancer Lett* 2017;408:138–
 1392 43. doi:10.1016/j.canlet.2017.08.022.

1393 [186] Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. *Matrix*
 1394 *Biol J Int Soc Matrix Biol* 2014;37:131–41. doi:10.1016/j.matbio.2014.03.001.

1395 [187] Oatley JM, Oatley MJ, Avarbock MR, Tobias JW, Brinster RL. Colony stimulating
 1396 factor 1 is an extrinsic stimulator of mouse spermatogonial stem cell self-renewal. *Dev Camb*
 1397 *Engl* 2009;136:1191–9. doi:10.1242/dev.032243.

1398 [188] DeFalco T, Potter SJ, Williams AV, Waller B, Kan MJ, Capel B. Macrophages
 1399 Contribute to the Spermatogonial Niche in the Adult Testis. *Cell Rep* 2015;12:1107–19.
 1400 doi:10.1016/j.celrep.2015.07.015.

1401 [189] Ushach I, Zlotnik A. Biological role of granulocyte macrophage colony-stimulating
 1402 factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid
 1403 lineage. *J Leukoc Biol* 2016;100:481–9. doi:10.1189/jlb.3RU0316-144R.

1404 [190] Chitu V, Gokhan S, Nandi S, Mehler MF, Stanley ER. Emerging Roles for CSF-1
 1405 Receptor and its Ligands in the Nervous System. *Trends Neurosci* 2016;39:378–93.
 1406 doi:10.1016/j.tins.2016.03.005.

1407 [191] Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang Y-L, Pei D, et al. Targetable
 1408 Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. *N Engl J Med*
 1409 2014;371:1005–15. doi:10.1056/NEJMoa1403088.

1410 [192] Lilljebjörn H, Ågerstam H, Orsmark-Pietras C, Rissler M, Ehrencrona H, Nilsson L, et
 1411 al. RNA-seq identifies clinically relevant fusion genes in leukemia including a novel
 1412 MEF2D/CSF1R fusion responsive to imatinib. *Leukemia* 2014;28:977–9.
 1413 doi:10.1038/leu.2013.324.

1414 [193] Schwab C, Andrews R, Chilton L, Elliott A, Richardson S, Ryan SL, et al. SSBP2-
 1415 CSF1R Is a Recurrent Fusion in B-Other Acute Lymphoblastic Leukaemia with Variable
 1416 Clinical Outcome. *Blood* 2014;124:3773–3773.

1417 [194] Iwamoto S, Mihara K, Downing JR, Pui C-H, Campana D. Mesenchymal cells
 1418 regulate the response of acute lymphoblastic leukemia cells to asparaginase. *J Clin Invest*
 1419 2007;117:1049–57. doi:10.1172/JCI30235.

1420 [195] Fung K-L, Liang RH-S, Chan GC-F. Vincristine but not imatinib could suppress
 1421 mesenchymal niche's support to lymphoid leukemic cells. *Leuk Lymphoma* 2010;51:515–22.
 1422 doi:10.3109/10428190903406798.

1423 [196] Paget S. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF
 1424 THE BREAST. *The Lancet* 1889;133:571–3. doi:10.1016/S0140-6736(00)49915-0.

1425 [197] Fidler IJ, Nicolson GL. Organ selectivity for implantation survival and growth of B16
 1426 melanoma variant tumor lines. *J Natl Cancer Inst* 1976;57:1199–202.

1427 [198] Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, et al. Pre-
 1428 metastatic niches: organ-specific homes for metastases. *Nat Rev Cancer* 2017;17:302–17.
 1429 doi:10.1038/nrc.2017.6.

1430 [199] Duarte D, Hawkins ED, Celso CL. The interplay of leukemia cells and the bone
 1431 marrow microenvironment. *Blood* 2018;131:1507–11. doi:10.1182/blood-2017-12-784132.

1432 [200] Boyerinas B, Zafrir M, Yesilkanal AE, Price TT, Hyjek EM, Sipkins DA. Adhesion to
 1433 osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. *Blood*
 1434 2013;121:4821–31. doi:10.1182/blood-2012-12-475483.

1435 [201] Rooij B de, Polak R, Berk LCJ van den, Stalpers F, Pieters R, Boer ML den. Acute
 1436 lymphoblastic leukemia cells create a leukemic niche without affecting the CXCR4/CXCL12
 1437 axis. *Haematologica* 2017;haematol.2016.159517. doi:10.3324/haematol.2016.159517.

1438 [202] Balandrán JC, Purizaca J, Enciso J, Dozal D, Sandoval A, Jiménez-Hernández E, et al.
 1439 Pro-inflammatory-Related Loss of CXCL12 Niche Promotes Acute Lymphoblastic Leukemic
 1440 Progression at the Expense of Normal Lymphopoiesis. *Front Immunol* 2017;7.
 1441 doi:10.3389/fimmu.2016.00666.

1442 [203] Cheung LC, Tickner J, Hughes AM, Skut P, Howlett M, Foley B, et al. New
 1443 therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.
 1444 *Leukemia* 2018;1. doi:10.1038/s41375-018-0144-7.

1445 [204] Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, et al. T-
1446 cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments.
1447 Nature 2016;538:518–22. doi:10.1038/nature19801.

1448 [205] Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al.
1449 VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.
1450 Nature 2005;438:820–7. doi:10.1038/nature04186.

1451 [206] Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Mark MT, et al.
1452 Tumour exosome integrins determine organotropic metastasis. Nature 2015;527:329–35.
1453 doi:10.1038/nature15756.

1454 [207] Boyiadzis M, Whiteside TL. The emerging roles of tumor-derived exosomes in
1455 hematological malignancies. Leukemia 2017;31:1259–68. doi:10.1038/leu.2017.91.

1456 [208] Johnson SM, Dempsey C, Chadwick A, Harrison S, Liu J, Di Y, et al. Metabolic
1457 reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute
1458 lymphoblastic leukemia. Blood 2016;128:453–6. doi:10.1182/blood-2015-12-688051.

1459 [209] Johnson SM, Dempsey C, Parker C, Mironov A, Bradley H, Saha V. Acute
1460 lymphoblastic leukaemia cells produce large extracellular vesicles containing organelles and
1461 an active cytoskeleton. J Extracell Vesicles 2017;6. doi:10.1080/20013078.2017.1294339.

1462 [210] Berridge MV, McConnell MJ, Grasso C, Bajzikova M, Kovarova J, Neuzil J.
1463 Horizontal transfer of mitochondria between mammalian cells: beyond co-culture approaches.
1464 Curr Opin Genet Dev 2016;38:75–82. doi:10.1016/j.gde.2016.04.003.

1465 [211] Polak R, Rooij B de, Pieters R, Boer ML den. B-cell precursor acute lymphoblastic
1466 leukemia cells use tunneling nanotubes to orchestrate their microenvironment. Blood
1467 2015;126:2404–14. doi:10.1182/blood-2015-03-634238.

1468 [212] Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D. Bone marrow-
1469 derived stromal cells prevent apoptotic cell death in B- lineage acute lymphoblastic leukemia.
1470 Blood 1992;79:2370–7.

1471 [213] Ashley DM, Bol SJ, Kannourakis G. Human bone marrow stromal cell contact and
1472 soluble factors have different effects on the survival and proliferation of paediatric B-lineage
1473 acute lymphoblastic leukaemic blasts. Leuk Res 1994;18:337–46.

1474 [214] Shah N, Oseth L, LeBien TW. Development of a Model for Evaluating the Interaction
1475 Between Human Pre-B Acute Lymphoblastic Leukemic Cells and the Bone Marrow Stromal
1476 Cell Microenvironment. Blood 1998;92:3817–28.

1477 [215] Pal D, Blair HJ, Elder A, Dormon K, Rennie KJ, Coleman DJL, et al. Long-term in
1478 vitro maintenance of clonal abundance and leukaemia-initiating potential in acute
1479 lymphoblastic leukaemia. Leukemia 2016;30:1691–700. doi:10.1038/leu.2016.79.

1480 [216] Mudry RE, Fortney JE, York T, Hall BM, Gibson LF. Stromal cells regulate survival
1481 of B-lineage leukemic cells during chemotherapy. Blood 2000;96:1926–32.

1482 [217] Filshie R, Gottlieb D, Bradstock K. VLA-4 is involved in the engraftment of the
1483 human pre-B acute lymphoblastic leukaemia cell line NALM-6 in SCID mice. Br J Haematol
1484 1998;102:1292–300. doi:10.1046/j.1365-2141.1998.00899.x.

1485 [218] Shishido S, Bönig H, Kim Y-M. Role of Integrin Alpha4 in Drug Resistance of
1486 Leukemia. Front Oncol 2014;4. doi:10.3389/fonc.2014.00099.

1487 [219] Krenacs T, Rosendaal M. Connexin43 gap junctions in normal, regenerating, and
 1488 cultured mouse bone marrow and in human leukemias: their possible involvement in blood
 1489 formation. *Am J Pathol* 1998;152:993–1004.

1490 [220] Rosendaal M, Mayen A, de Koning A, Dunina-Barkovskaya T, Krenács T, Ploemacher
 1491 R. Does transmembrane communication through gap junctions enable stem cells to overcome
 1492 stromal inhibition? *Leukemia* 1997;11:1281–9.

1493 [221] Liu Y, Zhang X, Li Z, Chen X. Up-regulation of Cx43 expression and GJIC function
 1494 in acute leukemia bone marrow stromal cells post-chemotherapy. *Leuk Res* 2010;34:631–40.
 1495 doi:10.1016/j.leukres.2009.10.013.

1496 [222] Zhang X, Liu Y, Si Y, Chen X, Li Z, Gao L, et al. Effect of Cx43 gene-modified
 1497 leukemic bone marrow stromal cells on the regulation of Jurkat cell line in vitro. *Leuk Res*
 1498 2012;36:198–204. doi:10.1016/j.leukres.2011.10.001.

1499 [223] Paraguassú-Braga FH, Borojevic R, Bouzas LF, Barcinski MA, Bonomo A. Bone
 1500 marrow stroma inhibits proliferation and apoptosis in leukemic cells through gap junction-
 1501 mediated cell communication. *Cell Death Differ* 2003;10:1101–8.
 1502 doi:10.1038/sj.cdd.4401279.

1503 [224] Sinyuk M, Alvarado AG, Nesmiyanov P, Shaw J, Mulkearns-Hubert EE, Eurich JT, et
 1504 al. Cx25 contributes to leukemia cell communication and chemosensitivity. *Oncotarget*
 1505 2015;6:31508–21. doi:10.18632/oncotarget.5226.

1506 [225] Akers SM, Rellick SL, Fortney JE, Gibson LF. Cellular elements of the subarachnoid
 1507 space promote ALL survival during chemotherapy. *Leuk Res* 2011;35:705–11.
 1508 doi:10.1016/j.leukres.2010.12.031.

1509 [226] Pedersen M, Löfstedt T, Sun J, Holmquist-Mengelbier L, Pålman S, Rönstrand L.
 1510 Stem cell factor induces HIF-1 α at normoxia in hematopoietic cells. *Biochem Biophys Res*
 1511 *Commun* 2008;377:98–103. doi:10.1016/j.bbrc.2008.09.102.

1512 [227] Ghajar CM. Metastasis prevention by targeting the dormant niche. *Nat Rev Cancer*
 1513 2015;15:238–47. doi:10.1038/nrc3910.

1514 [228] Manjili MH. Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution
 1515 to a Disease State. *Cancer Res* 2017;77:2564–9. doi:10.1158/0008-5472.CAN-17-0068.

1516 [229] Wick MR. Metastases of malignant neoplasms: Historical, biological, & clinical
 1517 considerations. *Semin Diagn Pathol* 2018;35:112–22. doi:10.1053/j.semdp.2017.11.009.

1518 [230] Groot AE de, Roy S, Brown JS, Pienta KJ, Amend SR. Revisiting Seed and Soil:
 1519 Examining the Primary Tumor and Cancer Cell Foraging in Metastasis. *Mol Cancer Res*
 1520 2017;15:361–70. doi:10.1158/1541-7786.MCR-16-0436.

1521 [231] Elder A, Bomken S, Wilson I, Blair HJ, Cockell S, Ponthan F, et al. Abundant and
 1522 equipotent founder cells establish and maintain acute lymphoblastic leukaemia. *Leukemia*
 1523 2017;31:2577–86. doi:10.1038/leu.2017.140.

1524 [232] Belderbos ME, Koster T, Ausema B, Jacobs S, Sowdagar S, Zwart E, et al. Clonal
 1525 selection and asymmetric distribution of human leukemia in murine xenografts revealed by
 1526 cellular barcoding. *Blood* 2017;129:3210–20. doi:10.1182/blood-2016-12-758250.

1527 [233] van der Velden VHJ, de Launay D, de Vries JF, de Haas V, Sonneveld E, Voerman
 1528 JSA, et al. New cellular markers at diagnosis are associated with isolated central nervous

1529 system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia. *Br J Haematol*
1530 2016;172:769–81. doi:10.1111/bjh.13887.

1531 [234] Jeha S, Pei D, Raimondi SC, Onciu M, Campana D, Cheng C, et al. Increased Risk for
1532 CNS Relapse in Pre-B Cell Leukemia with the t(1;19)/TCF3-PBX1. *Leuk Off J Leuk Soc Am*
1533 *Leuk Res Fund UK* 2009;23:1406–9. doi:10.1038/leu.2009.42.

1534 [235] Frishman-Levy L, Izraeli S. Advances in understanding the pathogenesis of CNS acute
1535 lymphoblastic leukaemia and potential for therapy. *Br J Haematol* 2017;176:157–67.
1536 doi:10.1111/bjh.14411.

1537 [236] Krause S, Pfeiffer C, Strube S, Alsadeq A, Fedders H, Vokuhl C, et al. Mer tyrosine
1538 kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the
1539 central nervous system (CNS). *Blood* 2015;125:820–30. doi:10.1182/blood-2014-06-583062.

1540 [237] Gandemer V, Rio A-G, de Tayrac M, Sibut V, Mottier S, Ly Sunnaram B, et al. Five
1541 distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-
1542 positive leukemia. *BMC Genomics* 2007;8:385. doi:10.1186/1471-2164-8-385.

1543 [238] Gandemer V, Aubry M, Roussel M, Rio A-G, de Tayrac M, Vallee A, et al. CD9
1544 expression can be used to predict childhood TEL/AML1-positive acute lymphoblastic
1545 leukemia: proposal for an accelerated diagnostic flowchart. *Leuk Res* 2010;34:430–7.
1546 doi:10.1016/j.leukres.2009.09.033.

1547 [239] Ly-Sunnaram B, Henry C, Gandemer V, Mee FL, Burtin F, Blayau M, et al. Late
1548 ovarian relapse of TEL/AML1 positive ALL confirming that TEL deletion is a secondary
1549 event in leukemogenesis. *Leuk Res* 2005;29:1089–94. doi:10.1016/j.leukres.2004.11.027.

1550 [240] Churchman ML, Mullighan CG. Ikaros: Exploiting and targeting the hematopoietic
1551 stem cell niche in B-progenitor acute lymphoblastic leukemia. *Exp Hematol* 2017;46:1–8.
1552 doi:10.1016/j.exphem.2016.11.002.

1553 [241] Gerby B, Veiga DFT, Kros J, Nourreddine S, Ouellette J, Haman A, et al. High-
1554 throughput screening in niche-based assay identifies compounds to target preleukemic stem
1555 cells. *J Clin Invest* 2016;126:4569–84. doi:10.1172/JCI86489.

1556 [242] Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, et al. A phase 1 study
1557 of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide
1558 in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A
1559 Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
1560 *Pediatr Blood Cancer* 2017;64. doi:10.1002/pbc.26414.

1561 [243] Randhawa S, Cho BS, Ghosh D, Sivina M, Koehrer S, Müschen M, et al. Effects of
1562 pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell
1563 acute lymphoblastic leukaemia. *Br J Haematol* 2016;174:425–36. doi:10.1111/bjh.14075.

1564 [244] Hsieh Y-T, Gang EJ, Geng H, Park E, Huantes S, Chudziak D, et al. Integrin alpha4
1565 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy.
1566 *Blood* 2013;121:1814–8. doi:10.1182/blood-2012-01-406272.

1567 [245] Hsieh YT, Gang EJ, Shishido SN, Kim HN, Pham J, Khazal S, et al. Effects of the
1568 small-molecule inhibitor of integrin $\alpha 4$, TBC3486, on pre-B-ALL cells. *Leukemia*
1569 2014;28:2101–4. doi:10.1038/leu.2014.182.

1570 [246] de Gramont A, Faivre S, Raymond E. Novel TGF- β inhibitors ready for prime time in
1571 onco-immunology. *Oncoimmunology* 2016;6. doi:10.1080/2162402X.2016.1257453.

1572 [247] Wang Y, Liu Y, Malek SN, Zheng P, Liu Y. Targeting HIF1 α Eliminates Cancer Stem
1573 Cells in Hematological Malignancies. *Cell Stem Cell* 2011;8:399–411.
1574 doi:10.1016/j.stem.2011.02.006.

1575 [248] Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab
1576 for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous
1577 Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm
1578 Phase II CheckMate 205 Trial. *J Clin Oncol* 2018;36:1428–39.
1579 doi:10.1200/JCO.2017.76.0793.

1580 [249] Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II Study
1581 of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin
1582 Lymphoma. *J Clin Oncol Off J Am Soc Clin Oncol* 2017;35:2125–32.
1583 doi:10.1200/JCO.2016.72.1316.

1584

1585 **Conflict of Interest Statement**

1586 All authors declare to have no conflict of interest to disclaim.

1587 **Funding**

1588 This work has been funded by the Rennes Hospital FHU CAMin (CHU de Rennes), Brittany
1589 Regional Council (Région Bretagne), Comprehensive Cancer Center Eugène Marquis, and the
1590 Cancer Care Foundation LCC 35 (Ligue Contre le Cancer)

FIGURE LEGENDS




Figure 1. Clonal evolution of leukemic cells from preleukemic stage to relapse. A first genetic hit, such as an ETV6-RUNX1 rearrangement, in a hematopoietic progenitor leads to the apparition of a preleukemic clone, which can subsequently accumulate other genetic alterations to give rise to leukemic “ancestral clones”. Such clones may be present before birth, as notably shown for ETV6-RUNX1. Further genetic hits favor the emergence of clones that give rise to an overt acute lymphoblastic leukemia (ALL), which may be composed of a major clone and minor clones. After diagnosis, treatment of ALL with chemotherapy can eradicate all or almost all leukemic cells. Some cells from the bulk population may survive and give rise to a relapse with the same major clone found at diagnosis (situation C). Alternatively, cells derived from either major or minor clones may undergo other genetic alterations, leading to a different type of relapse, as shown in situations B and D. Relapsed leukemia may also derive from another ancestral clone or even directly from the preleukemic clone, which may have evolved on their own (situations A and E).




Figure 2. Main sites of acute lymphoblastic leukemia (ALL) relapse. (A) Bone marrow.

This extensively simplified schematic view of the bone marrow (BM) illustrates where ALL cells are mainly found in the perivascular spaces close to the endosteum. The endosteum

1610 corresponds to a thin layer of conjunctive tissue delineating BM and covered with osteoblasts
1611 and osteoclasts, which participate in balancing the renewal and remodeling of bone tissue.
1612 CXCL12-abundant reticular cells, specialized stromal cells near vessels, produce CXCL12,
1613 which appears to be necessary for ALL cell engraftment in BM. (B) *Testis*. Testis is the organ
1614 in which male gametes are produced. Germ-cell maturation takes place in specialized
1615 structures called seminiferous tubules, which are surrounded by an interstitial tissue and
1616 regrouped into lobules. The lobules are separated by fibrous septa which are in continuity
1617 with the capsular region. The testis is encapsulated in a fibrous covering called the tunica
1618 albuginea. The production of germ cells begins at the basement membrane, which surrounds
1619 the seminiferous tubule and where germ cells are the most immature. The germ cells mature
1620 as they progress from the basal part of the tubule to the lumen, where fully mature sperm cells
1621 are found. Throughout the maturation process, germ cells are enclosed by Sertoli cells, which
1622 form tight junctions between themselves to protect the germ cells and compartmentalize the
1623 maturation steps. The role of the blood-testis barrier is to protect germ cells from potentially
1624 deleterious molecules or cells. The blood-testis barrier is anatomically composed of the
1625 basement membrane, Sertoli cells, and their tight junctions, but does not encompass blood
1626 vessels, making the term “blood-testis barrier” inaccurate. Between the seminiferous tubules,
1627 the interstitial tissue, or interstitium, is composed mainly of supportive cells, called Leydig
1628 cells, of which one of the main roles is to produce testosterone. During testicular leukemia,
1629 ALL cells are mainly found in the interstitial perivascular spaces, and occasionally in
1630 seminiferous tubules, but only at very advanced stages of the disease, following inappropriate
1631 treatment. (C) *Central nervous system*. The central nervous system (CNS) consists of the
1632 brain, cerebellum, and spine. CNS tissue is surrounded by three meningeal layers: the thick
1633 dura mater, the arachnoid membrane, from which trabeculae fibers cross the subarachnoid
1634 space to reach the third thin layer, the pia mater, which is in direct contact with CNS tissue.

Cerebrospinal fluid circulates in the subarachnoid space, where blood vessels are found. When the CNS is involved, ALL cells localize mainly in the subarachnoid space, close to vessels, whereas some cells may circulate freely in the cerebrospinal fluid.




Figure 3. Potential therapeutic strategies to target the leukemic niche. The leukemic niche is a highly complex microenvironment made of many components or aspects that could be targeted. Potential niche-based treatments are represented by the darts, which could be used simultaneously to target different components, as symbolized by the blurry delineations on the target.

1645 Table 1. Examples of studies using molecules that target components of the leukemic niche.

Target	Study [ref]	Type of study	Tested molecule	Number of patients	Main results/comments
CXCL12/CXR4 axis	Cooper et al., 2017 [243]	Phase I	Plerixafor	20 (5 ALL, 12 AML, 1 AML/MDS)	Maximum dose 15 g/m ² without DLT Heavily pretreated patients Plerixafor administrated prior to chemotherapy (HD-araC + VP16) Mobilization of lymphoblasts achieved No clinical response in ALL patients (4 SD, 1 PD)
	Juarez et al., 2007 [124]	Preclinical (animal study)	Plerixafor, TC14012, AMD3465	NA	Reduced extramedullary engraftment of ALL cells in xenografted mice Mobilization of ALL cells in PB and spleens of xenografted mice Continuous administration equivalent to intermittent administration
	Ranhawa et al, 2016 [244]	Preclinical (<i>in vitro</i> and animal study)	Plerixafor, BKT140, CXCR4 genetic deletion	NA	Reduced chemotaxis of B-ALL cells Restoration of drug sensitivity of resistant B-ALL cells co-cultured with BMSCs Delayed engraftment and prolonged survival of mice xenografted with CXCR4-deleted B-ALL cells
	Juarez et al. 2003, [105]	Preclinical (<i>in vitro</i> study)	Plerixafor, TC14012	NA	Reduced chemotaxis of B-ALL cells Reduced proliferation of B-ALL cells cultured on stromal BM cells

Target	Study [ref]	Type of study	Tested molecule	Number of patients	Main results/comments
					Augmentation of inhibitory effects of chemotherapy
Integrin alpha4	Hsieh et al. 2013 [245]	Preclinical (<i>in vitro</i> and animal study)	Natalizumab	NA	Prolonged survival of xenografted mice Synergistic effect with chemotherapy (marked prolonged survival) Reduced engraftment in liver, spleen, and BM of xenografted mice and enhanced engraftment in lungs.
	Hsieh et al. 2014 [246]	Preclinical (<i>in vitro</i> and animal study)	TBC3486	NA	Reduced chemoresistance of B-ALL cells Prolonged survival of xenografted mice Synergistic effects with chemotherapy <i>in vivo</i>
HIF1a	Badar et al., 2016 [146]	Phase I	TH-302 (evofosfamide)	49 (39 AML, 9 ALL, 1 CML)	Heavily pretreated patients 5 days of administration over 21-day cycles Maximum tolerated dose 460 mg/m ² as intermittent administration and 330 mg/m ² as continuous infusion. 1 patient with T-ALL with PR
	Benito et al. 2016 [147]	Preclinical (<i>in vitro</i> and animal study)	TH-302 (evofosfamide)	NA	Cytotoxicity on B-ALL cells in hypoxic culture conditions Not tested in an <i>in vivo</i> ALL model
	Konopleva et al. 2015 [145]	Phase I/II	PR104	50 (40 AML, 10 ALL[3 T-ALL, 7 B-ALL])	Heavily pretreated patients Chosen doses for phase II: 3 g/m ² and 4g/m ² 2 responses (1 CR and 1 MLFS) in 7 B-ALL
	Benito et al. 2011 [141]	Preclinical (<i>in vitro</i> and animal	PR104	NA	Cytotoxicity on B-ALL cells in hypoxic culture conditions

Target	Study [ref]	Type of study	Tested molecule	Number of patients	Main results/comments
		study)			Delayed engraftment of mice xenografted with B-ALL cells Prolonged survival of xenografted mice with maintained complete response at 550 mg/kg
Restoring normal microenvironment	Cheung et al, 2018 [203]	Preclinical (<i>in vitro</i> and animal study)	Zolendronic acid	NA	Reduced leukemia burden in xenografted mice with B-ALL cells Prolonged survival of mice xenografted with B-ALL cells
Immune system	Chen et al. 2017, [250]	Case report	Nivolumab	2	Heavily pretreated patients with one or two prior HSCTs Off-label use Low-dose nivolumab (40-80 mg/course) administered to prevent GVHD Clinical response with the 2 patients alive 13 months and 4 months after relapse, but with persistent disease
	Boekstegers et al. 2017 [251]	Case report	Pembrolizumab	1	Refractory T-ALL treated with HSCT followed by 4 DLIs Fast clinical response with MRD decrease Severe acute GVHD, leading to immunosuppressive treatment with subsequent re-increase of MRD, multi-organ failure, and death

Table 1. Examples of studies using molecules that target components of the leukemic niche. The apparently disappointing results from clinical studies may be explained by the use of new treatments mostly alone in heavily pretreated patients. The association of each of these

1650 molecules with each other and/or conventional chemotherapy or immunotherapy might lead to
1651 better outcomes.

1652 Abbreviations: AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; BM:
1653 bone marrow; BMSC: bone marrow stem-cell; CML: chronic myeloid leukemia; CR:
1654 complete remission; DLI: donor lymphocyte infusion; DLT: dose-limiting toxicity; GVHD:
1655 graft versus host disease; HD-AraC: high-dose aracytine; HSCT: hematopoietic stem cell
1656 transplantation; MLFS: morphological leukemia-free state; MRD: minimal residual disease;
1657 NA: not applicable; PB: peripheral blood; PD: progressive disease; PR: partial response; SD:
1658 stable disease